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0163-7258/© 2020 The Author(s). Published by Elsevier Ia b s t r a c ta r t i c l e i n f oAvailable online 28 June 2020Keywords:The DNA-PK holoenzyme is a fundamental element of the DNA damage responsemachinery (DDR), which is re-
sponsible for cellular genomic stability. Consequently, and predictably, over the last decades since its identifica-
tion and characterization, numerous pre-clinical and clinical studies reported observations correlating aberrant
DNA-PK status and activity with cancer onset, progression and responses to therapeuticmodalities. Notably, var-
ious studies have established in recent years the role of DNA-PK outside the DDR network, corroborating its role
as a pleiotropic complex involved in transcriptional programs that operate biologic processes as epithelial tomes-
enchymal transition (EMT), hypoxia, metabolism, nuclear receptors signaling and inflammatory responses. In
particular tumor entities as prostate cancer, immense research efforts assistedmapping and describing the over-
all signaling networks regulated by DNA-PK that control metastasis and tumor progression. Correspondingly,
DNA-PK emerges as an obvious therapeutic target in cancer and data pertaining to various pharmacological
approaches have been published, largely in context of combination with DNA-damaging agents (DDAs) that
act by inflicting DNA double strand breaks (DSBs). Currently, new generation inhibitors are tested in clinical tri-
als. Several excellent reviews have been published in recent years covering the biology of DNA-PK and its role in
cancer. In the current article we are aiming to systematically describe the main findings on DNA-PK signaling in
major cancer types, focusing on both preclinical and clinical reports and present a detailed current status of the
DNA-PK inhibitors repertoire.
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The DNA-dependent protein kinase catalytic subunit (DNA-PKcs),
encoded by the PRKDC/XRCC7 gene, is a pivotal DNA damage response
(DDR) player and with 460kD also the largest member of the
phosphatidylinositol-3-kinase-related protein kinase family (PIKK)
that includes also theDDRmaster kinases ataxia-telangiectasiamutated
(ATM) and ataxia-telangiectasia mutated and Rad3-related (ATR)
(Blackford and Jackson, 2017). Apart of the 3DDRkinases, the PIKK fam-
ily includes also mTOR, SMG1 and TRRAP (Lempiainen and Halazonetis,
2009).
Togetherwith theKuheterodimer that consists of the Ku70 (XRCC6)
and Ku80 (XRCC5) subunits, DNA-PKcs forms the DNA-PK holoenzyme
complex that is the core component of the non-homologous end-
joining (NHEJ) machinery, which alongside homologous recombination
(HR), comprise the two major canonical pathways for DNA double
strand breaks (DSBs) repair.
NHEJ entails several steps that cover the detection of DSBs by the
Ku70/80 ring-shaped heterodimer with subsequent recruitment, as-
sembly and stabilization of the NHEJ complex at the damage location
and finally, the enzymatic activation of DNA-PKcs, which leads eventu-
ally to ligation of broken DNA ends (Davis and Chen, 2013). While the
homologous template-dependent HR is largely restricted to the S and
G2 cell cycle phases, NHEJ is essentially active during G0 and G1 phases,
however, it may still be functional through all cell phases (Trenner and
Sartori, 2019). It has been suggested for example that pathway choice
between HR and NHEJ during S phase is regulated through an interac-
tion between the tumor suppressor protein BRCA1 and theDNA-PK reg-
ulatory subunit Ku80, which stabilizes the Ku heterodimer at DSBs, a
step that is required for end-joining repair through NHEJ in the G1
phase (Saha and Davis, 2016). As aforementioned, at occurrence of
DSBs, DNA-PKcs is rapidly recruited by the Ku70/80 heterodimer to
the affected DNA lesions, at which two units of DNA-PKcs interact
with two heterodimers of Ku70/80 to assemble the DNA-PK complex
(Grundy et al., 2014). The formation of the holoenzyme on DNA stimu-
lates the catalytic activity of DNA-PKcs, which is manifested by its auto-
phosphorylation and a subsequent phosphorylation of NHEJ effectors
including Ku70, Ku80, the scaffold proteins XRCC4 and XLF, the
structure-specific endonuclease Artemis, and the polynucleotide ki-
nase/phosphatase PNKP (Blackford and Jackson, 2017; Davis et al.,
2014). The autophosphorylations of DNA-PKcs on Thr2609/2647 and
Ser2056, in the ABCDE and PQR clusters, respectively, are involved in
regulation of its DNA end-processing DSBs repair activity (Cui et al.,
2005; Jiang et al., 2015). Within its function in the DDR and apart of
being a critical mediator of cellular response to constantly occurring
DSBs, DNA-PKcs is responsible for the rejoining of programmed DSBs
that are generated during V(D)J recombination and class switching re-
combination in the course of B and T lymphocytes maturation (Chang
et al., 2017; Franco et al., 2008). Additionally, the NHEJ is the predomi-
nant pathway for DSBs resulting from exposure to ionizing radiation
(IR) and it is considered to be responsible for the rapid repair of up to
85% of IR-induced DSBs (Mahaney et al., 2009).
The very high cellular levels of DNA-PK (Anderson and Carter, 1996)
have suggested that apart of NHEJ, this complexmay be involved also in
global pathways that are not linked to DNA repair. Indeed, and aside of
its well-characterized DDR-associated functions, the DNA-PK complex
has also been shown to have a hold over multiple cellular processes in-
cluding transcriptional regulation. In fact, one of the first studies to re-
veal DNA-PK's biologic function demonstrated a DNA-PK-regulated
phosphorylation of the SP1 transcription factor upon its binding to GC
transcriptional regulatory elements in the context of SV40 early genes
transcription (Jackson et al., 1990). Shortly then after, Dvir et al. re-
ported in 1992 that DNA-PK regulates RNA polymerase II through phos-
phorylation in the presence of DNA and the TFIID, TFIIB, and TFIIF
transcription factors (Dvir et al., 1992). During the last two decades, a
myriad of findings (reviewed in (Goodwin and Knudsen, 2014)) havelinked DNA-PK to regulation of transcription of various cellular net-
works that control among others expression of immune effectors,
tumor suppressors andhormone receptors such as the androgen and es-
trogen receptors that play critical roles in human cancer (Goodwin and
Knudsen, 2014). Additionally, DNA-PK can directly phosphorylate the
glucocorticoid and the progesterone receptors (Giffin et al., 1997;
Sartorius et al., 2000).
In recent years, DNA-PK has been also correlatedwith keymetabolic
processes such as fatty acids synthesis and glucose metabolism (Wang
et al., 2015; Wong et al., 2009), reviewed in (Chung, 2018). In that re-
spect,Wonget al. suggested already back in 2009 that DNA-PK regulates
insulin-associated transcription of fatty acid synthase, a key lipogenesis
player (Wong et al., 2009). Later, the inhibition of DNA-PK has been
linked to improved insulin sensitivity and to protection against type 2
diabetes through its regulation of phosphorylation of AMP-activated
protein kinase (AMPK) and increased mitochondrial function (Park
et al., 2017). Among other pleiotropic non-DDR cellular functions of
DNA-PK, the most notable are its involvement in the protection of telo-
meres length (Bailey et al., 1999;Williams et al., 2009), regulation ofmi-
tosis (Jette and Lees-Miller, 2015), for example through its interaction
with polo-like kinase 1 (Douglas et al., 2014), and functional control of
cytoplasmic organelles such as the Golgi apparatus (Farber-Katz et al.,
2014). Recently, a manuscript by Shao et al. provided evidence that
DNA-PKcs has a DNA repair-independent, but crucial role in ribosomal
RNAbiogenesis, which is primarily dependent on Thr2609 cluster phos-
phorylation (Shao et al., 2020). Interferencewith Thr2609 phosphoryla-
tion resulted in global protein synthesis deregulation and eventual bone
marrow failure (Shao et al., 2020).
Anomalous DDR signaling, affecting either cell cycle checkpoints or
DNA repair elements, has beenfirmly associatedwith cancer propensity
and may alter tumor cell responses to DNA-damaging agents, largely
used in clinical oncology. Therefore, DDR pathwaysmake an ideal target
for therapeutic intervention. As several reviews in recent years have
covered overall aspects of DNA-PK biology under physiologic and
deregulated conditions, here we aim to systematically overview and
discuss pre-clinical and clinical findings pertaining to the role of the
DNA-PK system across common human cancer types.
2. DNA-PK in cancer – General aspects of preclinical observations
Initial observations evidencing that aberrant NHEJ signaling leads to
genomic instability and eventual carcinogenesis originated largely from
genetically-modified animal-based studies that generated mice with
DNA-PK ablations (reviewed in (Mohiuddin and Kang, 2019)). The
early studies assessing biologic consequences of a compromised NHEJ
have focused on the impact of Ku70- and Ku80-deficiency on cellular
models and mice. Overall, Ku70- and Ku80-deficient cells and mice
were shown to exhibit radiation hypersensitivity and defective NHEJ
with associated obvious genomic instability features as chromosomal
aberrations and aneuploidy (S. Chen et al., 2001; Difilippantonio et al.,
2000; Ferguson et al., 2000; Gu et al., 1997a, 1997b; Lee et al., 2016;
Nussenzweig et al., 1997). As might be envisaged with a faulty NHEJ
pathway, Ku-deficient animals have aberrant V(D)J recombination
with resultant abnormalities in the maturation processes of both B
and T lymphocytes (Gu et al., 1997a, 1997b; Li et al., 1998). Li et al. re-
ported in late 1990's that mice with Ku70 depletion develop T cell lym-
phoma (Li et al., 1998) while mice depleted of Ku80 on a deficient p53
background develop at young age a lymphocytic malignancy that ex-
hibits features similar to Burkitt's lymphoma (Difilippantonio et al.,
2000). With respect to DNA-PKcs, the severe combined immune-
deficiency (SCID) mouse (Bosma et al., 1983) harbors a spontaneously
occurring mutation in the PRKDC gene (Finnie et al., 1995;
Kirchgessner et al., 1995; Peterson et al., 1995), leading to an83-aa trun-
cation of the C-terminal end of the protein (Blunt et al., 1996; Danska
et al., 1996). Consequently, DNA-PKcs levels in these mice are only
about 10% compared to wild type animals, and DNA-PK activity is
3M. Medová et al. / Pharmacology & Therapeutics 215 (2020) 107617considerably reduced (Danska et al., 1996; Woo et al., 1998). SCIDmice
are highly radiosensitive and exhibit profound T and B cell deficiency
due to a defective V(D)J. Additionally, the animals present with short-
ened telomeres and a subsequent accelerated aging.
Among the first works to assess the impact of DNA-PKcs deficiency
in carcinogenesis was a study by the group of Gloria Li who reported
in 1999 that mice with a DNA-PKcs disruption demonstrate a predispo-
sition for the development of hyperplastic polyps and abnormal crypt
foci in the intestine (Kurimasa et al., 1999). A complementary later
study by Espejel et al. reported that DNA-PKcs-ablated aged mice
showed increased incidence of thymic lymphomas in addition to other
features including short telomeres, smaller body size and overall earlier
onset of age-related pathologies (Espejel et al., 2004). In addition to
these findings, naturally occurring mutations in PRKDC in BALB/C
mice, affecting codons 2140 (R2140C) and 3844 (M3844V), have been
correlated with increased susceptibility to IR-induced genomic instabil-
ity andmammary epithelial cells transformation (Yu et al., 2001). It has
been previously reported that IR-induced DNA-PKcs activation through
phosphorylation at the Thr2609 cluster is predominantly regulated by
ATM(B. P. Chen et al., 2007).Mechanistically, it was shown that ablation
of DNA-PKcs Thr2609 cluster phosphorylation results in a considerable
increase in basal and radiation-induced telomere fusions (Williams
et al., 2009). Homozygous knock-inmice harboring threonine to alanine
substitutions at the Thr2605 cluster (Thr2605A, Thr2634A and
Thr2643A) die shortly after birth due to bone marrow failure and this
severe phenotype manifestation can be rescued through bone marrow
transplantation (Zhang et al., 2011). Interestingly, in 2016 Zhang et al.
reported that mice with loss-of-function phosphorylation at DNA-PKcs
cluster Thr2605 develop a range of tumors including lymphomas, hepa-
tocellular carcinoma and squamous cell carcinoma as of 15weeks of age
after being rescued through bonemarrow transplantation (Zhang et al.,
2016).
In addition to the studies focusing on the correlation between
deregulated DNA-PK and cancer, similar observations within the con-
text of pre-clinical models have been reported and linked loss-of-func-
tion of other NHEJ players as LIG4, XLF and XRCC4, mainly on a p53-
null background, to the development of particular tumors such as sar-
coma (Sharpless et al., 2001), B-cell lymphoma (Gao et al., 2000) and
medulloblastoma (G. Li et al., 2008; C. T. Yan et al., 2006).
3. DNA-PK expression and signaling in human malignancies
An immense body of experimental data has been collected over the
years on the roles of DNA-PK in human cancer. The data that corelate al-
terations as CNVs (Fig. 1), expression patterns (Fig. 2) and signaling of
DNA-PK components with tumor onset, progression and responses to
therapies, may be distinct and vary in individual malignancies. In this
chapterwe review cancer types-specific peculiaritieswith respect to ex-
pression, SNPs (Table 1), downstream signaling and the pleiotropic in-
teractions of the DNA-PK complex with other cellular networks
(Fig. 3). Additionally, studies referring to DNA-PK-related interference
with anti-cancer therapeutic modalities and to DNA-PK targeting in
context of different tumor types are discussed.
3.1. Breast cancer
A first significant observation correlating a DNA-PK genetic aberra-
tion with breast tumorigenesis was reported by the 2001 Yu et al.
study that described two different PRKDC single nucleotide polymor-
phisms (SNPs) as a basis for a high-risk breast carcinogenesis in BALB/
C mice following exposure to IR (Yu et al., 2001). A later work by
Fabre et al. suggested that this polymorphism is functionally underlying
a deficiency of DNA-PKcs expressionwith consequent compromising ef-
fects on DNA repair and telomere function (Fabre et al., 2011). Respec-
tively, polymorphisms in the promoters of the Ku70 and Ku80 subunits
of DNA-PK have been correlatedwith either increased or decreased riskin several human tumors, including breast cancer. Accordingly, both the
Ku70 C-61G polymorphism (SNP rs2267437) and the Ku80 promoter
polymorphism G-1401 T (SNP rs828907) were associated with an ele-
vated risk for the development of breast cancer (Willems et al., 2009).
Conversely, the XRCC6 A46922G SNP rs132793 variant was suggested
to relate to a decreased breast cancer risk (Jia et al., 2015; Sobczuk
et al., 2010). Mechanistically, it is to be anticipated that at least in
some of SNPs, mutations in promoters of DNA-PK components interfere
with transcription regulation, thereby affecting eventually NHEJ overall
functioning. A confirmation for that was provided by a study by Quimet
et al. who found that the Ku70 C-61G variant (rs2267437C > G) sub-
stantially changes transcriptional activity in an allele-specific manner
and influences the DNA-protein complex formation in breast cancer
cell lines (Ouimet et al., 2012).
A number of studies reported observations pointing to the relevance
of DNA-PKcs and the Ku70 and Ku80 subunits expression levels to
breast cancer pathogenesis. These findings have associated DNA-PK de-
creased expressionwith increased frequency of chromosome instability
and consequent clinical parameters as larger tumors, higher tumor
grade and axillary lymph node metastasis (Someya et al., 2007). A sim-
ilar correlation has been observed in tumors with lower Ku70 and Ku80
expression (Someya et al., 2007). Tumors expressing low levels of DNA-
PKcs were also associated withworse breast survival regardless the sta-
tus of the estrogen receptor (Abdel-Fatah et al., 2014a, 2014b). Likewise,
DNA-PK lower activity in peripheral blood lymphocytes, which was de-
termined by using a DNA-pull-down assay, was found to correlate with
a risk for breast and uterine cervix cancer (Someya et al., 2006).
Apart of the impact of promoter polymorphism, among other poten-
tialmechanisms leading to deregulated DNA-PK expression, the CDK12/
Cyclin K complex has been reported to affect genome stability through
the regulation of RNA polymerase II activity, which controls the tran-
scription of various DDR components, including BRCA1 and FANC1
(Blazek et al., 2011). In 2018, Naidoo et al. reported that CDK12 can be
either highly expressed or absent in patient breast cancer samples. Im-
portantly, CDK12 deficiency was associated with reduced expression of
several DDR proteins including both Ku70/Ku80 and DNA-PKcs (Naidoo
et al., 2018). These findings advocate a novel mechanism of CDK12 in
DNA-PK dysregulation in breast cancer, with possible future therapeutic
implications.
In another work, Li et al. reported nuclear bFGF to mediate chemo-
therapy resistance of triple-negative breast cancer (Li et al., 2015). The
study showed that chemo-residual triple-negative tumor cells with in-
creased bFGF nuclear presence manifest also elevated levels of both
DNA-PKcs and Ser2056 phosphorylated, activated DNA-PKcs. Further-
more, high nuclear bFGF localization was associated with an elevated
DNA-PK-based DNA damage repair activity.
With respect to therapeutic responses, a 2010 study by Söderlund
Leifler et al. that correlated DNA-PK levels in a cohort of 224 breast can-
cer patients with response to radiotherapy, reported that patients with
lower Ku70/Ku80 levels had better outcome at early stages of the dis-
ease (Soderlund Leifler et al., 2010). Similar observations in the same
studywere found for patients with higher levels of DNA-PKcs. Addition-
ally, high nuclear Ku70/80 levels were correlated in breast cancer with
various parameters of poor prognosis as higher histopathological
grade, lymphvascular invasion, absence of estrogen receptor and a
basal-like phenotype (Alshareeda et al., 2013). Similarly, the Ku70/80
heterodimer was shown to be expressed and bound to chromatin at el-
evated levels in advanced breast cancer compared to hyperplastic and
normal breast cells (Abdelbaqi et al., 2013).
Various DNA-PK-relatedmechanisms that may affect treatmentmo-
dalities have been described in breast cancer (Lees-Miller et al., 2016;
Medunjanin et al., 2010; Rubin et al., 2007; Ter Brugge et al., 2016).
For example, Ku70, Ku80 and DNA-PKcs were identified as HOXB7-
binding proteins, an interaction, which may contribute to IR resistance
in mammary epithelial cells due to an enhanced NHEJ activity (Rubin
et al., 2007). Interestingly, two estrogen receptor-alpha (ER-alpha)-
Fig. 1. The fraction of cases with a mutation (left) or CNV event (right) for the PRKDC, XRCC5 and XRCC6 genes in individual TCGA projects on various cancer types. The data has been
obtained from the GDC Data Portal (https://portal.gdc.cancer.gov/genes/ENSG00000253729 for PRKDC, for example). More details on the UCEC project, for example, can be obtained at
https://portal.gdc.cancer.gov/projects/TCGA-UCEC.
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scribed and reported to enhance breast cancer cells to repair DNA dam-
age, which could lead to therapy resistance (Medunjanin et al., 2010).
Likewise, the long non-coding RNA LINP1 has been suggested as a scaf-
fold, which links Ku70/80 andDNA-PK, allowing an efficient DSBs repair
through the NHEJ pathway and contributing to the resistance of breast
cancer to IR and chemotherapy (Lees-Miller et al., 2016).
On the other hand, an interference with DNA-PK function by a trun-
cated RAF1 splice variant, Raf1-tr, which shows increased nuclear local-
ization and binds DNA-PK, sensitizes various cancer cells, including
those of breast origin, towards IR and the radiomimetic bleomycin
(Nixon et al., 2019). Different new DNA-PK-based strategies have been
studied to sensitize breast cancer cells to IR and chemotherapeutic
drugs. For example, the peptide HNI-38 inhibits DNA-PK activity
through the disruption of the interaction between the Ku heterodimer
and DNA-PKcs (Kim et al., 2002). Also, the DNA-PK inhibitors NU7441
and KU-55933 showed sensitization to IR and doxorubicin due to the
accumulation of DNA damage (Ciszewski et al., 2014; Cowell et al.,
2005). Likewise, an increased DNA damage has been observed in
BRCA1-BER-deficient cancer cells treated with DNA-PK inhibitors
alone or in combinationwith cisplatin (Albarakati et al., 2015). Interest-
ingly, a study investigating the signaling interphase between EGFR and
DNA-PK reported that the EGFR inhibitor gefitinib reduced DNA-PKcs
nuclear levels and increased its cytosolic localization, which was corre-
lated to a decreased function of DNA-PKcs (Friedmann et al., 2006).
These works reflect the potential significance of DNA-PK targeting in
sensitizing breast cancer cells to IR and chemotherapy.
DNA-PK has been also pointed to play an active role in the carcino-
genesis of breast cells. Anandi et al. showed in a 2017 study that DNA-PK is in fact driving the transformation process of normal breast cells
following treatment by an alkylating agent (Anandi et al., 2017). The
authors found that exposure of breast epithelial cells to N-methyl-N-
nitrosourea resulted in an altered function of the cellular Golgi appara-
tus that led to an epithelial-to-mesenchymal transition (EMT)-like
phenotype and cell transformation. Inhibition of DNA-PK was in turn
able to completely reverse the altered Golgi phenotype and to partially
rescue the cells from the EMT-like alterations.
Earlier this year, a link between DNA-PKcs and autophagy has been
described inMCF-7 breast cancer cells (Puustinen et al., 2020). The pro-
vided data suggest that DNA-PKcs mediates the phosphorylation of the
AMP-dependent protein kinase (AMPK) subunit PRKAG1/AMPKγ1 that
subsequently primes AMPK complex to the lysosomal activation,
thereby linking DNA-PK to autophagy and cellular metabolism.
3.2. Cervical cancer
Mutations and CNV alterations in the genes encoding the catalytic
and regulatory subunits of DNA-PK are often present in cervical cancer
(Fig. 1). Interestingly though, the expression levels of the Ku70 and
Ku80 regulatory subunits particularly, seem to correlate most with pa-
tients outcome and treatment responses as indicated by various studies.
A 2000 report by Wilson et al. on cervical carcinoma biopsies has re-
vealed that tumors with low Ku70 protein expression weremore radio-
sensitive and correlated with a significantly better patient survival
(Wilson et al., 2000). Similar results were obtained with respect to the
correlation between Ku80 expression and response to radiation therapy
and survival. Harima et al. reported in 2003 that a low expression of the
Ku80 protein leads to radiosensitivity in cervical cancer patients and
Fig. 2. (A) Distributions of normalized expression values of the PRKDC, XRCC5 and XRCC6 genes in primary tumor samples (Primary Solid Tumor or Primary Blood Derived Cancer) in
individual TCGA projects on various cancer types. Only the projects with at least 100 primary tumor samples are shown. We use here the transcriptomics data made available by the
Pan-Cancer Atlas initiative (https://gdc.cancer.gov/about-data/publications/pancanatlas). The Pan-Cancer Atlas initiative compares the 33 tumor types profiled by The Cancer Genome
Atlas (TCGA). The expression data use Fragments Per Kilobase of transcript per Million (FPKM) with Upper-Quartile (UQ) normalization and possible batch effects have been removed.
(B) Correlations between log-transformed normalized expressions of the PRKDC, XRCC5 and XRCC6 genes in primary tumor samples (Primary Solid Tumor or Primary Blood Derived
Cancer) in individual TCGA projects. Only the projects with at least 100 primary tumor samples are shown.
5M. Medová et al. / Pharmacology & Therapeutics 215 (2020) 107617predicted that Ku80 plays a role in treatment outcome (Harima et al.,
2003). Additionally, a study by Saygili et al. suggested that although
Ku70 expression may not be a prognostic marker in endometrial carci-
nomapatients, disease-free survivalwas found to be significantly higher
in patients with low percentage of Ku70-positive tumor cells (Saygili
et al., 2004).Table 1
SNP variants in genes encoding the DNA-PK complex for which correlations with clinical param
SNP Gene Function/Association
rs7003908 PRKDC/XRCC7 (DNA-PKcs G6721T) • increased cancer risk
• splicing regulation, mRNA instability
rs8178158 PRKDC/XRCC7 (DNA-PKcs) • increased cancer risk
rs828907 XRCC5 (Ku80 G-1401 T) • increased cancer risk
rs132793 XRCC6 (Ku70 A46922G) • decreased cancer risk
rs2267437 XRCC6 (Ku70 C-61G) • increased cancer risk
• affects transcriptional activity (Ouime
rs5751129 XRCC6 (Ku70 T-991C) • increased cancer risk
• low mRNA and protein expression inKu80 and Ku70 have been evaluated as potential predictive bio-
markers for patients with stage IB-IIA cervical carcinoma treated with
preoperative brachytherapy and radical surgery. However, although
tumor tissues express these proteins in contrast to normal epithelium,
no correlation of their expression with radiation response has been
found (Beskow et al., 2006). A subsequent 2009 retrospective study ofeters have been reported.
Cancer type
(Sipley, J.D. et al., 1995)
CRC (Sishc and Davis, 2017), prostate (Mandal, Kapoor, &
Mittal, 2010), glioma (Wang et al., 2004)
metastatic melanoma (Liang et al., 2012)
breast (H. C. Wang, et al., 2009), CRC (M. D. Yang et al.,
2009b), gastric (J. Q. L, et al., 2011), head and neck (Hsu
et al., 2009)
breast (Jia, Ren, Yan, Xiao, & Sun, 2015; Sobczuk et al.,
2010)
t et al., 2012)
breast (Willems et al., 2009)
NPC (Huang et al., 2015)
CRC, head and neck, gastric cancer (M. D. Yang, Wang,
Chang, Tsai, & Bau, 2011)
Fig. 3. DNA-PKcs-interacting proteins and its associated partners. The network composed of blue circles and full edges shows the DNA-PKcs interactome based on the STRING database
data (www.string-db.org), considering only experimentally confirmed interactors with high (0.700) confidence. Dashed edges lead to DNA-PKcs interactors and DNA-PKcs-associated
proteins, miRNAs or long non-coding RNA (lncRNA) especially relevant to particular cancer types; they are based on the findings of the literature included in this review. The exact
nature of their associations with DNA-PKcs is in detail described in the corresponding review sections.
6 M. Medová et al. / Pharmacology & Therapeutics 215 (2020) 107617IB-IIA cervical cancer patients receiving preoperative radiotherapy
followed by radical surgery has shown increased frequency of DNA-
PKcs-, Ku70- and Ku80-positive cells in residual tumors as compared
to the corresponding primary cancers, indicating a possible
radioresistance mechanism (Beskow et al., 2009). Another prognostic
study for locally advanced cervical cancer treated with cisplatin-based
chemoradiotherapy (CRT) found a marginal significance for 5-year sur-
vival difference between low and high expressors of DNA-PKcs (30% vs.
60%, p = .05) (Ho et al., 2017).
With respect to interference with the NHEJ pathway in cervical can-
cer, only a few of preclinical studies utilizing simple models have been
performed. In this respect, Tian et al. have reported back in 2007 that
the downregulation of DNA-PKcs and Ku70 using siRNAs in HeLa cells
leads to a decreased proliferation and increased apoptosis upon treat-
mentwith DDP (Tian et al., 2007). More recently, Vávrová et al. demon-
strated that DNA-PK inhibition by NU7441 in HeLa cells increases
phosphorylation of CHK1 and CHK2 upon a single dose irradiation of
8Gy, which contrasted with a complete blockade of CHK2 Thr68 andCHK1 Ser345 phosphorylations upon treatmentwith the ATMkinase in-
hibitor KU55933 and the ATR inhibitor VE-821, respectively (Vavrova
et al., 2016). NU7441 also mediated a strong G2 arrest 24 h post 15Gy
of IR that was coupled to the radiosensitizing effect of NU7441 only 72
h after irradiation, contrastingwith theVE-821-based radiosensitization
observed shortly post irradiation (Vavrova et al., 2016). Further studies
testing novel DNA-PK inhibitors in a broad spectrum of in vitro and
in vivo cervical cancer models are needed to uncover plausible clinical
potential of NHEJ targeting in these malignancies.
3.3. Colorectal cancer
Various findings that document genetic and signaling DNA-PK alter-
ations in colorectal cancer (CRC) predict its role in the pathogenesis of
this group of tumors. In an early 2001 study by Rigas et al., the expres-
sion levels of DNA-PK, Ku70 and Ku80 have been compared between
normal and human colon cancer tissues (Rigas et al., 2001). DNA-PK
levels were similar between both tissues but adenomas and carcinomas
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colon tissue, suggesting their implication in the development of colon
cancer. Using a small cohort of patient samples, a 2004 study reported
that DNA-PK activity as well as protein and mRNA levels of Ku70,
Ku80 and DNA-PKcs were elevated in CRC tissues (Hosoi et al., 2004).
As Ku80, Ku70 and DNA-PKcs have all consensus recognition elements
for the SP1 transcription factor in their promoters, the authors postu-
lated for a correlation between the elevated SP1 protein levels in
tumor tissues and the DNA-PK status. Using a cohort of 37 CRC patients,
all carriers of a KRAS codon 12 mutation, Ghezzi et al. reported in 2011
that Ku70 expression in poorly-differentiated tumors is significantly
higher than in well- and moderately-differentiated colorectal tumors
(Ghezzi et al., 2011). Additionally, downregulated Ku70 was linked
with poor disease-free survival in CRC and its loss of expression was
suggested to serve as a biomarker to predict poor prognosis (Lu et al.,
2014). With respect to treatment outcome and by referring to data
from a cohort of 96 patients with advanced rectal carcinoma, the ex-
pression pattern of Ku70 and Ku80 was shown as predictive for tumor
responses to radiation therapy (Komuro et al., 2002). Two genetic
DNA-PK SNPs have been reported in CRC: the Ku80 G1401T/SNP
rs828907 was associated with the development of CRC (Yang et al.,
2009a, 2009b) and the PRKDC intron 8 G6721T (SNP rs7003908) poly-
morphism with a significant increase risk in colon carcinogenesis
(Sishc and Davis, 2017).
The potential role of DNA-PK in colon cancer has been also investi-
gated in pre-clinical models of CRC. A small interfering RNA (siRNA) li-
brary screen with a subsequent validation through DNA-PKcs
downregulation, identified PRKDC as an essential gene in CRC cells
(S. Sun et al., 2016). The interference with DNA-PK signaling led to ap-
optosis, partially through AKT inhibition, and rendered CRC cells sensi-
tive towards chemotherapeutic agents that interfere with DNA
replication. Interestingly, a study from 2015 by Wilson et al. described
a link between the AIM2 inflammasome, a member of innate immune
sensors and a key player in host defence, and DNA-PK in colon carcino-
genesis. Through the use of Aim2-deficient mice that exhibit high CRC
burden, the study revealed that AIM2 interacts and limits the activation
of DNA-PK, which promotes AKT phosphorylation. Consequently, the
loss of AIM2 stimulated DNA-PK–mediated AKT activation, thereby en-
hancing tumor load (Wilson et al., 2015). In addition, the study byNixon
et al., which has been earlier introduced in the context of breast cancer,
found also that CRC HCT-116 cells showed reduced expression of the
new RAF1 splice variant, Raf1-tr, that associates with nuclear DNA-PK,
and that its introduction into the cells sensitized them to bleomycin-
induced apoptosis (Nixon et al., 2019).
The potential benefit of DNA-PK inhibitors has been studied in CRC
for several years. For example, KU-0060648, a dual inhibitor of DNA-
PK and PI3K, was shown to sensitize DNA-PK-deficient cells to
etoposide and doxorubicin and to reduce cell proliferation in vitro and
in vivo (Munck et al., 2012). More recently, the sensitivity to this com-
pound was linked to the loss of MMR proteins, such as MSH3 and
MLH1. Accordingly, these proteins have been suggested as biomarkers
for the identification of patients who could benefit from this therapy
(Hinrichsen et al., 2017). Moreover, the DNA-PK inhibitors NU7026
and IC486241 showed a synergistic effectwith the irinotecan activeme-
tabolite, SN38 and oxaliplatin due to an increased DNA damage
(Davidson et al., 2012a, 2012b).Within a study investigating properties
of the highly selective and potent CHK1 inhibitor V158411, it has been
observed that inhibition of CHK1 inHT-29 CRC adenocarcinoma cells ac-
tivatedDNA-PKcs as determined by increased its autophosporylation on
Ser2056 (Massey et al., 2016). The study shows that high expression of
DNA-PKcs, confers higher sensitivity to the CHK1 inhibitor V158411,
suggesting thereby that high DNA-PKcs levels might help to stratify pa-
tients with tumors highly sensitive to CHK1 inhibitors.
Also, DNA-PK inhibitors have been combined with the oncolytic
virus M1, reporting promising data as the inhibition of DNA-PK in-
creases the DNA damage induced by the virus, resulting in increasedcell death (Xiao et al., 2018). Interference with DNA-PKcs has also
been suggested to sensitize CRC cells to mTOR inhibitors (Wu et al.,
2015). Accordingly, DNA-PKcs Thr-2609 phosphorylation was shown
to be critical for resistance of HT-29 CRC cells to the mTOR inhibitor
WAY-600. The use of the DNA-PKcs inhibitors NU7026 and NU7441
significantly enhanced the WAY-600-induced cytotoxicity and pro-
apoptotic effect. These observations denote DNA-PKcs signaling as a rel-
evant resistance mechanism for mTOR targeting in CRC cells.
3.4. Gastric and esophageal cancer
As with tumors of other histotypes, promoter SNP variants of Ku70
and Ku80 were described also in gastric cancer. The Ku80 promoter G-
1401 T (rs828907) polymorphism was investigated in the context
with gastric cancer risk (J. Q. Li et al., 2011). Looking into a cohort of
241 patients, the findings suggest significant differences between gas-
tric cancer and control groups in the distribution of frequencies (P =
.002) in the G-1401 T polymorphism. Similarly, the Ku70 promoter T-
991C (rs5751129) variant has been reported to link to gastric cancer
predisposition (Yang et al., 2011).
Correlation between expression levels of DNA-PK and other NHEJ
proteins with intervention responses has been studied also in esopha-
geal and gastric cancers (Hori et al., 2017; Lee et al., 2005; Lee et al.,
2007; Noguchi et al., 2002; Tonotsuka et al., 2006). Esophageal cancer
patients with high DNA-PKcs-expressing tumors exhibited a greater
therapeutic benefit following chemoradiation modalities compared
with patientswith lower levels of DNA-PKcs (Noguchi et al., 2002). Sim-
ilarly, absence of DNA-PKcs expression has been associated with gastric
cancer progression, presence of intra-tumoral neutrophils, poor survival
(Lee et al., 2005; Lee et al., 2007) and lymph node metastasis (Lee et al.,
2005). Notably, DNA-PK expression exhibited a high intratumoral het-
erogeneity in patient samples of esophageal tumors, suggesting that
its activity or expression levelsmight not be good predictive biomarkers
of radio- or chemotherapy sensitivity (Tonotsuka et al., 2006). Absence
of DNA-PK expressionwas also determined in a subset of gastric cancers
characterized by high microsatellite instability (MSI-H) and was shown
to occur due a frameshift mutation of poly(A)10 mononucleotide re-
peats (H. S. Lee et al., 2007). MSI-H gastric cancer patients were more
likely to have lymph node metastasis and those carrying the poly(A)10
mononucleotide mutation had an increased risk compared to non-
carriers (H. S. Lee et al., 2007).
With respect to DNA-PK molecular targeting, plausible
radiosensitizing effects of the DNA-PK inhibitor NU7026 were reported
with the gastric cancer line N87 (Niazi et al., 2014). The combined
NU7026/irradiation treatment showed a significant increase in the
DNAdamagemarker histoneγH2AX, in G2/M cell cycle arrest and in ap-
optosis compared to administration of irradiation alone. These results
suggest that NU7026 enhances irradiation-mediated cytotoxic effect
resulting in an increase of DNA DSBs that arrest the cell cycle at the
G2/M checkpoint with consequent apoptosis (Niazi et al., 2014).
Recently, the role of the insulin-line growth factor binding protein 2
(IGFBP2) in esophageal adenocarcinoma (EAC) was determined (Zhou
et al., 2019). The development of EAC has been linked to chronic gastro-
esophageal reflux disease, which is characterized by the presence of
acidic bile salts (ABS). In this context, endogenous IGFBP2 knockdown
significantly increased DNA DSBs and apoptosis, while the overexpres-
sion of exogenous IGFBP2 had a protective effect against the
DNA DSBs and apoptosis caused by ABS. To determine the DDR
pathway involved in these findings, IGFBP2 was either knocked
down or overexpressed, resulting in a decreased and increased,
respectively, EGFR and DNA-PKcs phosphorylation. Moreover, co-
immunoprecipitation analyses determined that IGFBP2, EGFR and
DNA-PK co-localize in a protein complex upon ABS treatment and
IGFBP2 knockdown decreased the interaction between EGFR and
DNA-PK due to the unstable EGFR protein. Therefore, IGFBP2 expression
may protect EAC cells against DNA DSB and apoptosis induced by ABS
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the signaling axis activation (Zhou et al., 2019).
3.5. Glioblastoma multiforme and neuroblastoma
The role of DNA-PK in the context of glioblastoma multiforme
(GBM) and neuroblastoma has been investigated from different angles,
as responses to DNA-damaging agents, association with clinical param-
eters and as a target for radiosensitization.
Early preclinical research in the field underlined the association of
DNA-PK activation induced by staurosporine, ceramide and UV radia-
tion with apoptosis onset in neuroblastoma cells (Chakravarthy et al.,
1999) whereas studies by Virsik-Köpp et al. assessed the impact of
DNA-PK deficiency on the formation of chromosome aberrations in irra-
diated glioblastoma (Virsik-Kopp et al., 2003). It has been demonstrated
that radioresistant DNA-PK-proficient cell lines acquire less complex
aberrations and acentric chromosome fragments compared to their
DNA-PK-deficient counterparts and that DNA-PK inhibition by
wortmannin increases the aberration yield in the DNA-PK-proficient
model to the same qualitative and quantitative level as detected in the
DNA-PK-deficient line (Virsik-Kopp et al., 2003). Analogous GBM cellu-
lar systems have been used to study the regulation of DNA-PK activity
via theprotein kinase CK2. Downregulation of distinct CK2 catalytic sub-
units resulted in cell death in DNA-PKcs-proficient M059K cells but not
in the isogenic DNA-PKcs-deficient M059J line. Furthermore,
neocarzinostatin treatment of M059K cells depleted of either of the
CK2 catalytic subunits decreased Ser2056DNA-PK autophosphorylation
and inhibitedDNA-PKcs-mediated repair of DSBs, events likely resulting
from the disruption of a direct DNA-PK-CK2 interaction (Olsen et al.,
2010).
Translational relevance of these and similar mechanistic findings is
naturally dependent on the presence and activity of DNA-PK in patient
tumor tissues. The 2011 data by Kase et al. indicated that DNA-PK levels
correlatewith post-irradiation survival of post-surgery glioblastomapa-
tients (n = 34; 9.0 months for the group with low vs. 13.0 months for
the group with high DNA-PK expression) (Kase et al., 2011). In the con-
text of neuroblastoma, Saini et al. investigated mechanisms underlying
de-differentiation of neuroblastoma cells within a proteomic study. The
results validated by a tissue microarray of 30 neuroblastoma cases, and
found that the expression of DNA-PKcs is increased in advanced stages
(Saini et al., 2014). Correlation of enhanced PRKDC mRNA expression
and poor survival in neuroblastoma patients reported by Dolman et al.
provided a basis for their studies on the radiosensitization potential of
the DNA-PK small molecule inhibitor NU7026 (Dolman et al., 2015).
NU7026 formed a synergistic pro-apoptotic combination with a single
irradiation dose of 0.63Gy that was increasing with time and reaching
a maximum effect 96 h post irradiation (Dolman et al., 2015). Impor-
tantly, radiosensitization due to impaired NHEJ has been observed in
several neuroblastoma cell lines but not in normal fibroblasts with
low DNA-PK expression (Dolman et al., 2015).
Radiosensitization by the use of another DNA-PK small molecule in-
hibitor, VX984, has been recently investigated in in vitro and in vivo
models of glioblastoma. VX984 increased radiosensitivity of adherent
U251 and stem-like NSC11 cell lines in clonogenic assays and led to
higher γH2AX levels and DSBs in neutral comet analyses (Timme
et al., 2018). Moreover, VX984 in combination with IR increased overall
survival in comparison to IR alone in mice with orthotopic GBM xeno-
grafts, supporting the evaluation of DNA-PK inhibitors in GBM in clinical
trials (Timme et al., 2018).
3.6. Head and neck cancer (HNC)
Two SNP variants have been reported in the genes encoding Ku70
and Ku80 in head and neck cancers. The T-991C (SNP rs5751129) poly-
morphism located in the promoter region of the XRCC6 gene that en-
codes for KU70 has been correlated with significantly lower mRNAand protein expression levels in tissues of nasopharyngeal carcinoma
(NPC) patients (Huang et al., 2015). These data suggest that this Ku70
variant may play a role in the pathology of NPC and could serve as a fac-
tor for personalized medicine and therapy in this subset of HNC. An as-
sociation between the Ku80 promoter G-1401 T (rs828907) with oral
cancer risk was investigated in a cohort of 600 patients with oral cancer
compared with matched healthy controls (Hsu et al., 2009). The find-
ings published in 2009 suggested that Ku80 G-1401 T correlates with
oral cancer susceptibility. Additionally, the expression levels of the
DNA-PKcs protein have been investigated in 223 samples of NPC tissues
(Yan et al., 2008). DNA-PKcs levels were found to be a prognostic pre-
dictor of NPC with poor survival outcomes and possibly may play a
role in recurrent disease and metastasis.
As radiation therapy is a main therapeutic modality in HNC, it has
been of interest and need to investigate markers associated with radia-
tion response of these tumors. Considering their driving role inDDR, im-
munohistochemical expression of DNA-PKcs and Ku70/80 have been
determined in purpose to assess their relation with patient and tumor
characteristics and as plausible predictive markers (Bjork-Eriksson
et al., 1999). However, no significant correlation has been found be-
tween DNA-PKcs and Ku70/Ku80 expression and the site of tumor, pa-
tient age and sex, histology, or radiation response (Bjork-Eriksson
et al., 1999). In 2016, Lu et al. described amechanismmediated through
the Epstein-Barr virus-encoded protein LMP1, which attenuated DSBs
repair in NPC through the inhibition of DNA-PK activity, a path, which
also involved a disruption in the association between DNA-PK and the
AMP-dependent protein kinase (AMPK) and associated reduced AMPK
T172 phosphorylation (Lu et al., 2016). Eventually, those events result
in LMP1-dependent glycolysis and resistance to radiation-mediated
apoptosis.
Also in 2016, whole exome sequencing data analysis of head and
neck squamous cell carcinoma (HNSCC) revealed aberrations in Fanconi
anemia (FA) genes, leading to impaired DNA repair (Romick-Rosendale
et al., 2016). Interestingly, further investigations have shown that FA
pathway loss leads to cytoskeleton reorganization and invasive proper-
ties, a path mediated through RAC1 GTPase that can be reversed by
DNA-PK inhibition (Romick-Rosendale et al., 2016).
A meta-analysis of HNSCC datasets revealed a possible role of the
AAA+ATP-ase TRIP13/HPV16E1BP in treatment resistance of these tu-
mors (Banerjee et al., 2014). This hypothesis has been further investi-
gated by mass spectrometry, identifying DNA-PK as a TRIP13-binding
partner and, interestingly, overexpression of TRIP13 in HNSCC has
been associated with enhanced NHEJ activity and a consequent higher
sensitivity to DNA-PK inhibitors (Banerjee et al., 2014). These observa-
tions point to TRIP13 overexpression as a therapeutic marker for the
identification of DNA-PK inhibitors responders.
Establishment of a gene expression model analysis with the use of
machine learning tools enabled to uncover association between DNA
crosslink repair defects frequent in head and neck and aggressive tu-
mors, their chemoradioresistant properties and a poor patient progno-
sis. The subsequent in vitro experiments employing RAD51 inhibition
revealed induction of this aggressive phenotype while DNA-PK inhibi-
tion reduced it (Essers et al., 2019).
In a recent study comparing radiosensitization potency of PARP in-
hibitors (olaparib, veliparib) and DNA-PK inhibitors (KU57788,
IC87361) in HNSCC cell lines, KU57788 and IC87361 have beenmore ef-
fective than olaparib and veliparib, especially under hypoxia (T. W. Lee
et al., 2019). Additionally, the radiosensitizing effect of IC87361 was re-
lated and enhanced by the expression of the SLFN11/Schlafen-11
endoribonuclease that activates a cell death pathway in response to
DNA replication fork damage (Murai et al., 2018; Zoppoli et al., 2012).
3.7. Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a common humanmalignant dis-
order with a life expectancy of about 6 months as of the time of
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netic and environmental risk factors determines a broad genotypic
and phenotypic heterogeneity within human HCC (Donato et al.,
2006; Dragani, 2010). Several modalities as partial hepatectomy, radio-
frequency ablation, and liver transplantation are used as potential cura-
tive therapies (Sherman, 2011), however, only a small number of
patients can undergo these treatments due to advanced disease stage
at time of diagnosis (Calvisi et al., 2007; Llovet and Bruix, 2008;
Sherman, 2011). Currently, there is an urgent need for understanding
mechanisms underlying HCC progression that could provide novel op-
portunities for pharmacologic interventions.
Accumulating preclinical observations indicate an important role of
DNA-PKcs in HCC establishment, progression and patients' prognosis.
Although other types of liver cancers such as cholangiocarcinoma and
biliary cystadenocarcinoma show deregulated DNA-PKcs expression,
HCC is considered to have the highest expression of this critical NHEJ
component (Evert et al., 2013). DNA-PKcs has also been suggested to
be involved in HCC biology under low oxygen conditions as its levels
have been shown to be upregulated under hypoxia in HepG2 hepatoma
cells (Um et al., 2004a, 2004b). Moreover, DNA-PKcs may also interact
with, and phosphorylate HIF-1α, suggesting a potential regulation of
this hypoxia master transcription factor (Um, Kang, et al., 2004). Other
lines of evidence suggest also a crosstalk between DNA-PKcs and MYC
in HCC models. In that respect, Raymond et al. reported that DNA-
PKcs inhibited the proteolysis of MYC by suppressing its proteasomal
degradation in HepG2 cells (Raymond et al., 2015). The further rele-
vance of DNA-PKcs in regulating MYC was also observed using the
LO2 normal liver cells and demonstrating that overexpression of DNA-
PKcs is followed by increased MYC levels and associated upregulation
of AKT (Raymond et al., 2015).
Additionally to these findings, the heat shock transcription factor-1,
identified as a potential novel target with increased mRNA and protein
levels in human HCC, has been reported by Evert et al. to upregulate
DNA-PKcs through the activation of the MAPK/JNK/AP-1 axis (Evert
et al., 2013). Interestingly, and on the other hand, the regulatory DNA-
PK subunit Ku80 has been described as a tumor suppressor in HCC as
its overexpression suppresses cell proliferation in vitro and in vivo
(Wei et al., 2012). Moreover, in these models, Ku80 overexpression ar-
rests cell cycle at S-phase through the upregulation of p53 and p21,
which can be reversed by p53 or p21 inhibition (Wei et al., 2012).
The association between DNA-PK levels/activation and different cel-
lular endpoints such as proliferation or survival has been also assessed
in HCC. Activated DNA-PKcs increases proliferation, genomic instability,
microvessel density and has been associated with decreased apoptosis
(Evert et al., 2013) and poor survival (Cornell et al., 2015). Moreover,
high levels of DNA-PKcs have been identified in treatment-resistant
HCC patients, whose disease progressed at amedian of 4.5months com-
pared with 16.9 months (Cornell et al., 2015). This resistance was over-
come by the use of the DNA-PKcs inhibitor NU7441, which suppresses
HCC growth in vitro and in vivo in combinationwith irradiation or doxo-
rubicin (Cornell et al., 2015).
Collectively, these results suggest that DNA-PKcs activity is poten-
tially linked with pathways in the liver, which might have impact on
HCC development, progression and treatment responses.
3.8. Lung cancer
An early Sirzén et al. pre-clinical report back in 1999 studied the cor-
relation between DNA-PK levels in five lung carcinoma cell lines and re-
sponse of the cells to radiation in terms of DSBs repair and
radiosensitivity (Sirzen et al., 1999). Thefindings of this study suggested
that the lowest DNA-PK levels/activity was found in the most radiosen-
sitive cells, whilst the highest DNA-PK presencewas associatedwith the
lines displaying a radioresistant phenotype.
The expression of Ku80 in clinical lung adenocarcinoma specimens
and its role in the regulation of cisplatin sensitivity has beeninvestigated in a cohort of 106 patients with operable lung adenocarci-
noma (Ma et al., 2012). The work found that Ku80 was markedly
overexpressed in primary human lung adenocarcinoma and high Ku80
expression was associated with poor clinical outcomes and resistance
to cisplatin-based chemotherapy. Complementary to the clinical data,
siRNA-mediated knockdown of Ku80 enhanced the pro-apoptotic ef-
fects of chemotherapy of the cisplatin-resistant lung adenocarcinoma
cells A549/DDP that overexpress Ku80.
In a 2001 study by Auckley and colleagues, DNA-PK activity has been
correlated with carcinogenesis, progression as well as prediction of
treatment response in lung cancer. In a case control study comparing
stages I-IV newly diagnosed non-small cell lung cancer (NSCLC) pa-
tients and healthy individuals, the DNA-PK activity from peripheral
mononuclear cells was significantly lower in patients as compared to
healthy controls (Auckley et al., 2001). Importantly, this reflected the
status of DNA-PK activity in bronchial epithelial cells that are precursor
cells from which lung cancer may develop (Auckley et al., 2001).
Decrease in DNA-PK activity leading to genetic instability and lung
carcinogenesis has been mechanistically associated with radiation-
induced BCL-2 activation. BCL-2, a potent suppressor of apoptosis, was
shown to directly interact with Ku70 and Ku80 via its BH1 and BH4 do-
mains, leading to inhibition of DSBs repair via NHEJ (Q. Wang et al.,
2008). BCL2 expressionwas shown to correlatewith a reduced Ku activ-
ity in human lung cancer cells, advocating the possibility of BCL2 inter-
ference with the NHEJ pathway and the development of lung cancer.
Another reported mechanism for DNA-PK involvement in lung can-
cer is related to the suppressed activation of DNA-PKcs through the in-
hibitory effect of the Tudor domain-containing protein 9 (TDRD9).
TDRD9 is a RNA helicasewhose overexpression in lung adenocarcinoma
has been related to hypomethylation of theCpG islandwithin the5′ reg-
ulatory region of the gene. (Guijo et al., 2018). TDRD9 knockdown in
lung cancer cells elicited the activation of DNA-PKcs.
Whereas low DNA-PK activity may predispose to the development
of lung cancer, its higher activity on the other hand is likely used by can-
cer cells as a pro-survival path leading eventually to resistance towards
DNA damage-based therapeutic modalities. By a quantitative real-time
PCR analysis of 140 lung cancer patients tissues, it has been shown
that DNA-PKcs is significantly higher in the tumor when compared
with bordering normal tissue, a result linkedwith amore than twice in-
creased risk of death (Xing et al., 2008). Interestingly, when examining
mechanisms that account for DNA-damaging agents (DDAs) resistance
of lung cancer stem-like cells, Lundholm et al. found that those cells dis-
play a lesser phosphorylation status of DDR effectors, as ATM, KAP1 and
DNA-PK, indicating hence a reduced activity mode (Lundholm et al.,
2013).
With respect to early anti-DNA-PKcs perturbations, NSCLC cells un-
dergoing DNA-PKcs interference, either through down-regulation by
antisense oligodeoxynucleotides or exposure to wortmannin, showed
increased DNA DSBs and an enhanced radiation response (Sak et al.,
2002). Similarly, a Ku70 antisense approach in a human squamous cell
lung carcinoma cell line resulted in higher radiosensitivity and
chemosensitivity to bleomycin and methyl methanesulfonate (Omori
et al., 2002).
In a recent study using A549 humanNSCLC cells, a treatmentmodal-
ity combining the novel DNA-PKcs small molecule inhibitor M3814
along with carbon ion irradiation elicited high efficacy in eliminating
radioresistant hypoxic tumor cells (Klein et al., 2017).
As EGFR mutations and receptor amplification are relevant to the
lung cancer genomic landscape, the EGFR-DNA-PK axis has been stud-
ied in the context of responses to DNA damage-based treatment. Ac-
cordingly, Javvadi et al. reported a modulatory role for EGFR signaling
in DNA-PK-mediated DSB repair and radiation resistance of NSCLC.
The model for the EGFR-DNA-PK signaling interphase suggests that ini-
tial IR-induced ATM-dependent DNA-PKcs phosphorylation at Thr2609
is required for the interaction between nuclear EGFR and DNA-PKcs.
Moreover, the authors also found that EGFR regulates DNA-PKcs
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ing EGFRmutations as L858R or theΔE746-E750 in-frame deletion pre-
vent EGFR-DNA-PKcs interaction and compromise the stability of
Thr2609 phosphorylation that negatively affects eventual DSBs repair
(Javvadi et al., 2012). Similar NSCLC data showing the failure of EGFR
variants EGFR L858R and ΔE746-E750 to translocate to the nucleus, to
associate with DNA-PKcs and to elicit an EGFR-linked radioprotection
were reported also in an earlier work (Das et al., 2007). Taken together,
these observations suggest a careful stratification for the application of
EGFR-based radiosensitization protocols for NSCLC patients, which
should take into consideration the tumor EGFR status. Similar to other
tumors, activation of DNA-PK via AKT was also reported in the NSCLC
cell lines A549 and H460 (Toulany et al., 2008). In these models, AKT
signaling perturbation by AKT-targeting siRNA leads to failure of DSBs
repair (Toulany et al., 2008).
In a recent 2019 manuscript by Fok et al., another novel selective
DNA-PK inhibitor, AZD7648, demonstrated potent activity in both
in vitro and in vivomodels consisting of the A549 and H1299 lung ade-
nocarcinoma cell lines, in particular in the context of radiosensitizing
features (Fok et al., 2019). The in vitro data confirmed that AZD7648
leads to the persistence of DNA damage following IR, resulting in
G2/M DNA damage checkpoint activation, genome instability and re-
duced cellular survival. When tested in vivo, AZD7648 that was admin-
istered orally enhanced the response to fractionated IR in mice with
A549 or H1299 NSCLC xenografts. While tumors were insensitive to
single-agent AZD7648 treatment, IR treatment alone induced tumor
growth inhibition by 50%, but a combination of AZD7648 with IR
achieved 90% of growth inhibition. Parallel to these biologic conse-
quences in these NSCLC models, the IR-induced phosphorylations of
DNA-PKcs at Ser2056, γH2AX and RPA32 at Ser4/Ser8 were efficiently
blocked by AZD7648, indicating therefore the stabilization of the DNA
damage through the DNA-PKcs perturbation.
In summary and taking into account the different mechanistic as-
pects of DNA-PK activation in lung cancer, its therapeutic, prognostic
and predictive role need yet to be fully understood and assessed in
terms of precision oncology concepts for achieving a maximal impact
in current lung cancer management.
3.9. Lymphoma
Lymphoid tumors were among the first in which a role for the DNA-
PK system has been elucidated, primarily through the use of preclinical
models. An early biochemical characterization of DNA-PKcs with re-
spect to its autophosphorylation has been done in context of lymphoma
cells nearly 30 years ago by Iijima et al. Using Raji Burkitt's lymphoma
cells the work showed that DNA-PK autophosphorylation induces ser-
ine phosphorylation of MYC, and that this activity requires the presence
of double-stranded DNA (Iijima et al., 1992).
Homozygous Ku70 knockout mice develop T cell lymphomas,
whereas heterozygous littermates remain tumor-free. This observation
supports the potential function of the DNA-PK regulatory subunit Ku70
as a tumor suppressor gene for T cell lymphoma development (G. C. Li
et al., 1998). Further early studies employing knockout mice of the cat-
alytic subunit DNA-PKcs were instrumental in sheding light over DNA-
PKcs role in the immune system development. DNA-PKcs-null mice
show abnormalities in V(D)J recombination, increased radiosensitivity
and SCID-like phenotype but no increase in development of thymic lym-
phoma has been observed (Kurimasa et al., 1999). Instead, hyperplastic
polyps and aberrant crypt foci have been found in the intestines of DNA-
PKcs-null mice, suggesting similarly function of a tumor suppressor
gene (Kurimasa et al., 1999). Along the same line, Espejel et al. have re-
ported increased incidence of T cell lymphoma, shortened telomers and
earlier aging of DNA-PKcs-deficient mice on a longer follow-up analysis
(Espejel et al., 2004).
As in the context of tumors of other origins, numerous studies on
lymphoma have investigated the role of DNA-PK in responses toDDAs. As anticipated, allelic variations in the PRKDC gene coding for
DNA-PKcs resulted in differences in radiation sensitivity and
radiation-induced lymphomagenesis (Mori et al., 2001). Interestingly,
a correlation between BCR-ABL, the fusion that drives chronic myeloge-
nous leukemia, and DNA-PKcs has been reported by Deutsch et al. in
2001. Ectopic expression of BCR-ABL in haematopoietic cells was ac-
companied with strong decrease of DNA-PKcs levels. Accordingly,
proteasome-mediated DNA-PK degradation has been observed in stable
and inducible BCR-ABL-expressing cell lines, leading to genetic aberra-
tions and sensitivity to irradiation (Deutsch et al., 2001). A potential vi-
cious circle of defective DNA repair together with antiapoptotic activity
was shown to contribute to a blast crisis that could be reversed by pro-
teasome inhibitors through the prevention of DNA-PKcs degradation
(Deutsch et al., 2001).
Untreated lymphoma patient samples have been investigated in the
context of DNA-PKcs, Ku80, and Ku70 expression. According to data re-
ported by Holgersson et al., higher DNA-PKcs and Ku80 expression is
present in more aggressive tumors such as acute myeloid leukemia,
high-grade lymphoma, multiple myeloma, and is contrasting with
their lower expression in chronicmyeloid leukemia and low-grade lym-
phoma (Holgersson et al., 2004).
NK314, a dual inhibitor of topoisomerase IIα and DNA-PK, was re-
ported to overcome resistance to topoisomerase inhibitors in DNA-PK-
expressingM059K T-cell leukemia-lymphoma cell line, having a similar
effect as a combination of etoposide and NU7026, specific topoisomer-
ase and DNA-PK inhibitors, respectively (Hisatomi et al., 2011). DNA-
PK has been shown to be involved in olaparib-induced cytotoxicity in
ATM- and p53-mutatedmantle cell lymphoma cells, acting as a stabiliz-
ing agent formutated p53 (Williamson et al., 2012). Those data also cor-
respondwith experimental findings usingmousemodels lacking PARP1
and DNA-PK, showing their protective role in lymphoma formation
when p53 is mutated (Rybanska et al., 2013). Recently, early clinical tri-
als on dual TORK/DNA-PK inhibition (NCT01353625) have shown
promise for relapsed/refractory chronic lymphocytic leukemia (CLL)/
small lymphocytic lymphoma with ATM deletions/mutations (Thijssen
et al., 2016).
3.10. Melanoma
As etiology of melanoma is often linked to environmental factors
such as sun exposure, alterations in genes that repair exogenous DNA
damage, including the NHEJ pathway, might increase the disease risk.
Indeed, evaluation of DNA repair genes variants in 586 individuals
from 53 melanoma high-risk families has revealed four different
PRKDC polymorphisms (the most significant one being rs8178158) as
well as SNPs in the POLN gene as being significantly associated with
this pathology (Liang et al., 2012). When testing if levels of distinct
key DDR and replication proteins are prognostic biomarkers in mela-
noma, Song et al. found that XRCC5 (Ku80) overexpression relates to
significantly worse survival (Song et al., 2013). At that time it has
been already shown that metastatic melanoma cells express high levels
of proteins with potential antiapoptotic effects including DNA-PK and
EGFR and that themutually regulated activities of these two kinases im-
plicate their role in the malignant phenotype and treatment resistance
(Um et al., 2004a, 2004b).
Important mechanistic insights into metastasis regulation via DNA-
PKcs were provided by a 2015 preclinical study by Kotula et al. who re-
ported that increased DNA-PKcs activation stimulates angiogenesis,
melanoma cells migration ability and metastasis that can be reversed
by DNA-PK inhibition (Kotula et al., 2015). Interestingly, DNA-PKcs
pro-metastatic activity in melanoma is executed by regulation of secre-
tion rather than gene expression, of more than 80 distinct proteinswith
a consequent possible modification of the tumor microenvironment
(Kotula et al., 2015). These findings are further supported by experi-
mental indications that the modulation of DNA-PK function influences
immunobiology of both tumor as well as T cells. In a high-throughput
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shown to favorably alter a variety of immunomodulatory proteins in-
cluding increase inHLA-I expression and PD-L1 reduction in a heteroge-
neous panel of melanomas (Tsai et al., 2017). Following NU7441
treatment, T cells expressed increased levels of activation markers, co-
stimulatory molecules, cytokines and decreased expression of the co-
inhibitory receptors., thus conditioning their better response to T-cell
based immunotherapy (Tsai et al., 2017). Such data are highly promis-
ing in light of the fact that immunotherapies, which have revolutionized
melanoma treatment, lead as single-agent treatments to complete re-
gressions only in 5–20% of patients (Ascierto et al., 2019; Robert et al.,
2015).
Besides immunotherapies, targeting of the V600E-mutated BRAF
found in ca. 60% of melanoma cases has, often in combination with
MEK inhibitors, markedly improved patients' survival. However, due
to a rapid acquisition of therapy resistance, efficacies of new treatment
strategies and combinations, including DNA-PK targeting, are con-
stantly being assessed (N. Li et al., 2017; Margue et al., 2019; Shih
et al., 2016).
Although equally of melanocyte origin, uveal melanoma (UM), aris-
ing intraocularly, is a considerably different malignancy in terms of ge-
netic background as compared to the cutaneous form (van der Kooij
et al., 2019). In a recent study by Doherty et al., low sister-chromatide
exchange rate observed in UM cell lines prompted the investigators to
assessmRNA expression of NHEJ-related genes in the UMTCGA dataset.
Apart of an increased expression of PRKDC, XRCC5 and XRCC6 in UM, el-
evated NHEJ activity and DNA-PKcs activation has been detected
(Doherty et al., 2019). UMmodels have shown an increased sensitivity
and cell death towards DNA-PK-mediated inhibition of NHEJ byNU7026
or NU7441 administered as single agents aswell as in combinationwith
IR or inter-strand cross-linking agents as compared to other cancer
types including cutaneous melanoma (Doherty et al., 2019). In another
recent study by Dogrusöz et al., the authors evaluated the expression of
DNA repair-related genes in the Leiden cohort of 64 UMs and identified
PRKDC as a gene, which was highly expressed in cases with unfavorable
prognosis (Dogrusoz et al., 2019). DNA-PK inhibition by NU7026 led to
downregulation of the EMT-related transcription factor SNAIL1 and to
attenuation of proliferation in the primary as well as in metastatic UM
cell lines. These data strongly imply further investigations on DNA-
PKcs as a potential therapeutic target in UM.
3.11. Ovarian cancer
Based on Genomic Data Commons (GDC) data, ovarian cancer ranks
as a cancer type with the second most cases (27%) harboring PRKDC
CNV events (Fig. 1). Elevated expression of DNA-PKcs in ovarian serous
adenocarcinoma tissues associates with advanced disease, less favor-
able prognosis (Shin et al., 2016) and poor ovarian cancer-specific sur-
vival (Abdel-Fatah et al., 2014a, 2014b).
Certain insights into DNA-PK role in ovarian cancer therapeutic re-
sponseswere provided bydata of theMulticentre Italian Trial in Ovarian
Cancer-2 (MITO-2), which enrolled 820 advanced ovarian cancer pa-
tients assigned to receive carboplatin/paclitaxel or carboplatin/PLD
(Perrone et al., 2016). Although the two arms did not show difference
in progression-free and overall survival and no biomarker had signifi-
cant prognostic value as a result of tissue microarray analysis including
229 patients, high levels of DNA-PK and phosphorylated acetyl-
coenzyme A carboxylase correlated with negative prognosis in the
carboplatin/paclitaxel arm (Perrone et al., 2016).
As high-grade serous ovarian cancer is usually p53-mutated,
genomically unstable and develops treatment resistance, some aspects
of preclinical research on DNA-PK in ovarian cancer have been focusing
on its role in tumor cell fitness and in therapeutic resistances. In this re-
spect, Langland et al. that have profiled radiation response of a panel of
16 ovarian cancer cell lines reported that while their radioresistance is
primarily determined by mutated p53, the DNA-PK status of the cellsdefined through gene copy number and expression levels kinase activ-
ity for DNA-PK, have a lesser impact on their radiosensitivity
(Langland et al., 2010). On the other hand, early studies have already
supported an involvement of DNA-PK in ovarian cancer resistance to
platinum-based therapies. Cisplatin-induced decrease in DNA-PKcs ki-
nase activity, which was significantly higher in cisplatin-resistant cell
lines, reflected the extent of proteolysis of the catalytic subunit of
DNA-PK (Henkels and Turchi, 1997). At the same time, impaired DNA-
binding ability of the DNA-PK Ku subunits mirroring their decreased
expression levels, was observed in apoptotic ovarian carcinoma cells
following cisplatin treatment (Henkels and Turchi, 1997). In a later
study by Townsend et al., DNA-PK overexpression in human ovarian
carcinoma cells was linked with cisplatin resistance (Townsend et al.,
2002). Thework showed that cisplatin resistance could be overpowered
by TLK286, a Glutathione S-Transferase π-activated prodrug of an
alkylating agent. TLK286-induced destabilization of DNA-PKcs and the
Kuheterodimer implicatedDNA-PK inhibition as a potentialmechanism
of TLK286 cytotoxicity (Townsend et al., 2002). Later, Stronach et al. re-
ported that DNA-PK phosphorylates Ser473 of AKT in response to cis-
platin treatment in ovarian cancer resistant cell lines and suggested
that their resensitization via DNA-PK inhibition is an alternative strat-
egy to AKT inhibition that leads to toxicities independent of the DNA re-
pair pathways (Stronach et al., 2011).
A potential role of DNA-PK in paclitaxel chemoresistance has been
documented following ovarian cancer cell resensitization through the
overexpression of the NOTCH3- and DNA-PK-targeting miR-136
(Jeong et al., 2017). Furthermore, McCormick et al. have recently stud-
ied association between defects in NHEJ and resistance to PARP inhibi-
tion in 6 cancer cell lines and 47 primary cultures of ovarian cancer
(McCormick et al., 2017). Overall, 40% of the cultures had defective
NHEJ and did not respond to treatment with the PARP inhibitor
rucaparib whereas cells with defective HR repair and competent NHEJ
were rucaparib-sensitive (McCormick et al., 2017). In these lines, the
DNA-PK inhibitor NU7441 caused a rucaparib resistance in all sensitive
cultures independently of their HR functionality, outlining the impor-
tance of NHEJ status for PARP inhibition efficacy inmanagement of ovar-
ian cancer.
Although no general conclusions on the utility of DNA-PK inhibition
in the context of cytotoxic treatments of ovarian cancer can be drawn
from these studies, the rather clear association between DNA-PK over-
expression and worse patients prognosis and therapeutic responses
warrants further exploring of DNA-PK targeting in particular settings.
In 2019, Fok et al. reported on the effectiveness of the combination of
the novel selective DNA-PK inhibitor AZD7648 and doxorubicin in ovar-
ian cancer cells (Fok et al., 2019). The treatment decreased DNA-PKcs
Ser2056, H2AX Ser139 (γH2AX) and the replication protein A subunit
32 (RPA32) Ser4/Ser8 phosporylations at early time-points and later re-
sulted in increased levels of γH2AX and cleaved PARP1 as well as in the
reduction in cell viability as compared to doxorubicin alone. Wise et al.
have reported similar findings by using the DNA-PK inhibitor M3814
combined with PLD in ovarian cancer xenograft models (Wise et al.,
2019) and this treatment combination is currently under investigation
in the clinical trial NCT04092270.
3.12. Prostate cancer
Prostate cancer is one of the tumor entities in which the role of the
DNA-PK complex in the pathogenesis, progression and determination
of factors affecting responses to therapeutic modalities has been exten-
sively studied. This can be at least partly attributed to the comprehen-
sive findings evidencing the intricate crosstalk between the DNA-PK
complex and the androgen receptor (AR) system, a signaling system
that has a major driving role in prostate tumorigenesis (Debes and
Tindall, 2002).
One of the first observations linking DDR alterations in a prostate
cancer model with responses to DDAs is a 2004 report by Li et al. The
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gous mutated hMLH1 mismatch repair gene with consequent MSI, af-
fecting the genes for DNA-PKcs and two MRN complex effectors,
RAD50 and MRE1, exhibit hypersensitivity to the radiomimetic
bleomycin (Li et al., 2004).
As aforementioned, theunderstanding of the relevance of DNA-PK to
prostate cancer biology has been significantly enhanced with the iden-
tification that DNA-PK interacts with the AR. The original 2005 Mayeur
et al. study used tandemmass spectroscopy to identify AR to directly in-
teract, via its ligand-binding domain with both Ku70 and Ku80, and in-
directly with DNA-PKcs (Mayeur et al., 2005). Importantly, the work
provided the critical evidence that both the Ku regulatory subunits
and DNA-PKcs act as AR co-activators by enhancing its activity are in-
volved in the AR transcriptional process. Further support for the role
of DNA-PK in AR-related transcription was provided by the binding of
its Ku regulatory subunits to the AR-responsive prostate specific antigen
(PSA) promoter (Mayeur et al., 2005).
The liaison between AR and DNA-PK could be indirectly also implied
from the effect of doxazosin, an alpha-1-adrenergic inhibitor that in-
duces apoptosis of LNCaP androgen-dependent prostate cancer cells
(Arencibia et al., 2005).Microarray analysis for gene expression changes
in doxazosin-treated cell lines revealed downregulation of XRCC5 and
PRKDC (Arencibia et al., 2005), suggesting a potential relevance for the
depletion of Ku80 and DNA-PKcs in survival of an androgen-
dependent prostate cellular model.
A further insight as to the functional role of DNA-PK and AR interac-
tion has been demonstrated by a digitonin-based permeabilized cell
assay of the LNCaP prostate cancer cell line (Shank et al., 2008). DNA-
PK activity was shown to impact AR sub-cellular localization in vitro
through the use of a panel of activating ds-oligonucleotides. Subse-
quently, the AR nuclear export into the cytoplasm in this system could
be blocked with the DNA-PKcs inhibitor NU7026 (Shank et al., 2008).
A major significant contribution to the understanding of themecha-
nisms and consequences of the AR-DNA-PK signaling intersection, par-
ticularly in response to treatment modalities that act by eliciting
genotoxic damage, was provided by the Goodwin et al. study from
2013. This work demonstrated that androgen deprivation impedes the
ability of the AR to promote DNA damage repair. Essentially, DNA-
PKcs has been identified as a key target of AR after DNA damage and
the AR-DNA-PKcs circuit as a major effector of DNA repair and thera-
peutic resistance in prostate cancer (Goodwin et al., 2013). Active AR
was also shown to stimulate DNA-PKcs activity, as determined by in-
creased DNA-PKcs phosphorylation on Ser2056 and DNA-PKcs-specific
function. Reciprocally, DNA-PK was shown to potentiate AR function
along with DNA repair and transcriptional regulation of AR (Goodwin
et al., 2013).
An additional important observation supporting the interplay be-
tween the AR and DNA-PK systems was provided by Al-Ubaidi et al. in
2013. The study that investigated biopsies from prostate cancer patients
who underwent castration therapy looked into Ku70 status in the ana-
lyzed tissues. The authors reported that Ku70 binds directly to the AR
and that following castration therapy a reduction in Ku70 levels has
been observed in 12 out of 14 patients (Al-Ubaidi et al., 2013).
Another comprehensive 2015 study provided evidence supporting
DNA-PKcs as a direct master regulator of pro-metastasis programs in
prostate cancer (Goodwin et al., 2015). The work showed a direct activ-
ity of DNA-PKcs in the modulation of prostate cancer metastasis net-
works with consequent promotion of tumor migration and invasion.
DNA-PKcs has been found to be upregulated in clinical samples of ad-
vanced tumors and to be an independent marker for recurrent disease,
metastasis and poor disease prognosis. As a major proof of principle,
DNA-PKcs targeting with the specific inhibitor NU7441 was efficient
to reduce tumor dissemination and metastasis formation in an in vivo
model inwhich prostate tumor cells were injected systemically through
the tail vain. Further supportive evidence in this direction was provided
using patient tumor tissues that were used ex vivo as explants andtreated with DNA-PKcs inhibitor. NU7441 in this system effectively re-
duced the expression of metastatic effectors as PREX1, ROCK2, ITGB4,
and VAV3 (Goodwin et al., 2015).
In an attempt to get closer insights into networks which account for
prostate cancer progression, a 2019 study by Kothari et al. investigated
the overall kinome gene expression from a cohort of 545 patients and
matched the resulting transcriptional profiles with patients long term
clinical follow up data (Kothari et al., 2019). The data confirmed DNA-
PK expression to be highly correlated with metastatic prostate cancer
progression in high-risk cancer. Enrichment analysis identified the
WNTpathway as amajor DNA-PK interactorwith consequent activation
of theWNT-associatedLEF1 transcription factor. Interestingly,DNA-PKcs
targeting resulted in growth suppression of both androgen-dependent
and -independent tumor cells. These novel data further substantiate
DNA-PKasamaster regulator of prostate cancerprogression and suggest
WNT targeting as an additional potential interventionmodality.
The identification of a positive feedback signaling circuit
encompassing AR-mediated expression and activation of DNA-PKcs
and a reciprocal DNA-PKcs activation of the AR suggests that targeting
the AR along with DNA-PKcs inhibition and a genotoxic perturbation
might emerge as an effective therapeutic modality in prostate cancer. A
related 2017 study that investigated the relevance of AR splice variants
(ARVs) to prostate cancer treatment resistance found that ARVs induced
through androgen deprivation promote post-irradiation prostate tumor
cells survival throughdirectbinding toDNA-PKcs (Yinet al., 2017).DNA-
PKcs targeting by the specific inhibitor NU7441 significantly increased
cellular DSBs as indicated through γH2AX levels andwas accompanied
with enhanced prostate cancer cell death after irradiation.
In a recent 2019 study, Chatterjee et al. aimed at investigating the
mechanisms involved in the paradoxical phenomenon of growth inhibi-
tion of prostate cancer by supraphysiologic (SPA) androgens levels
(Chatterjee et al., 2019). Using various prostate cancer models, the au-
thors' findings support a critical role for DNA-PKcs in modulating
tumor cytotoxicity through a SPA-induced, AR-mediated DNA damage
mechanism. Mechanistically, the study showed that SPA reduces
Thr2609 phosphorylation, a step, which is required for DNA-PKcs disso-
ciation from the chromatin, thereby hindering the completion of DNA
repair via NHEJ, resulting in elevated and persistent levels of cellular
DNA damage. This study provides data to support a clinical evaluation
of SPA in combination with DNA-PKcs inhibitors and in patients with
AR amplification.
Another mechanism throughwhich DNA-PKmay affect cell survival
in prostate cancer involves the phosphorylation of IGF-binding protein
3 (IGFBP-3) (Cobb et al., 2006). In that respect, Cobb et al. have identi-
fied and characterized IGFBP-3 phosphorylation on Ser156 by DNA-PK
to be a critical step in the growth-inhibitory and apoptosis-promoting
activities of IGFBP-3. DNA-PK-mediated phosphorylation of IGFBP-3,
enhanced its nuclear accumulation and was found as a critical event
for its interaction with its nuclear binding partner RXRα to exert pro-
apoptosis activity.
Notably, DNA-PKcs has been implicated, similarly to PARP1, inmedi-
ating theoncogenic effects of the ETS transcription factor fusion product,
TMPRSS2:ERG,which is predominant in prostate cancer (Brenner et al.,
2011). Importantly, the ERG-DNA-PKcs association has been found in
human prostate cancer tissues only in ERG gene fusion-positive cases.
Site-directed mutagenesis revealed that Tyr373 of ETS is critically in-
volved in the direct binding to DNA-PKcs. As to the functional signifi-
cance of the physical association between DNA-PKcs and ETS gene
fusion products, the study found it is entailed for ETS-mediated down-
stream transcription aswell as cell invasion andmetastasis.
In order to get into further signaling circuits related to DNA-PK sig-
naling, Dylgjeri et al. used DNA-PK inhibition in a series of various pros-
tate cancer in vitro models as well as xenografts and patient-derived
explants to reveal novel DNA-PK networks via transcriptomics
(Dylgjeri et al., 2019). Data analysis indicated the modulation of path-
ways known to be regulated by DNA-PK, including androgen responses,
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fied DNA-PK-mediated pathways included EMT regulation, immune re-
sponse, and metabolic processes. The study also suggests the
investigation of a combinatorial strategy targeting DNA-PK/TOR kinase
(TORK) and AR,which is currently being evaluated in the clinical setting
in castration-resistant prostate cancer (NCT02833883).
From a prognostic perspective, expression of DNA-PKcs in prostate
cancer predicts recurrence after radiation therapy (RT) independently
of Gleason score as evidenced from TMA analysis of samples from 179
patients, where biochemical recurrence has been associated with posi-
tive DNA-PKcs nuclear staining (Bouchaert et al., 2012). Similar ten-
dency of correlation has been shown with biochemical recurrence
after permanent Iodine 125 interstitial brachytherapy in an analysis of
983 patient samples (Molina et al., 2016).
With respect to SNP variants, an intron 8-associated PRKDC/XRCC7
polymorphism G6721T/SNP rs7003908 has been identified to correlate
with a significantly increased risk of prostate carcinogenesis (Mandal
et al., 2010). The functional relevance of this polymorphism remains
still undefined, however, it has been predicted to regulate splicing and
lead tomRNA instability or form a haplotypewith other genetic changes
in other genes through a linkage disequilibriummechanism (L. E.Wang
et al., 2004).
DNA-PK activity has also been used as a readout for local tumor con-
trol by RT in prostate cancer patients. DNA-PK activity in peripheral
blood lymphocytes has been positively correlated in a cohort of 69 pa-
tients that were treated with 3D conformal radiotherapy and
intensity-modulated radiation therapy, in the context of treatment re-
sults from the local tumor control perspective and normal tissue toxicity
(Someya et al., 2017). Those data suggest the possibility for assessing RT
efficiency through a DNA-PK function via a simple blood test.
Altogether, thesefindings implicate DNA-PK to have crucial pleiotro-
pic and highly intricated roles in prostate cancer onset, progression and
treatment responses. The significant findings that demonstrate a tight
signaling interphase between DNA-PK and the AR system suggest treat-
ment modalities that consist of targeting both those driving molecular
components along with DDAs as a potential powerful strategy to be in-
stigated in prostate cancer. Implementation of precision oncology-
based stratifications would be necessary in order to ensure selection
of patients for specific treatment combination modalities.
4. DNA-PK as a therapeutic target
Abnormal expression and deregulation of DNA-PK function in vari-
ous humanmalignancies and its interference with the activity of thera-
peutic DDAs stimulated development of multiple DNA-PK inhibitory
strategies. Due to significant structural homology of DNA-PK and PI3K,
early attempts to interfere with DNA-PK activity were largely relying
on small molecule inhibitors directed against PI3K and their derivatives.
In addition, development of novel anti-DNA-PK approaches was utiliz-
ing a homology model of its ATP-binding site, DNA-PKcs-targeting
microRNAs (Piotto et al., 2018; Yan et al., 2010) or antibodies and inhib-
itors specific to the Ku heterodimer such as ScFv 18–2 or compound L
(Weterings et al., 2016; Xiong et al., 2012). In this chapter we will pre-
dominantly focus on the development of pharmacological approaches
interfering with the catalytic activity of DNA-PKcs as these compounds
are currently the most readily applicable in clinics. Whereas ongoing
clinical trials (Table 2) study the effects of a handful of these inhibitors
mostly in combination with chemo- or radiotherapy in distinct cancer
types, the roles of DNA-PK in tumor-associated processes outside of
DNA repair and in cancers with particular genetic deficiencies still
need to be thoroughly exploited.
4.1. Identification and evaluation of preclinical DNA-PK inhibitors
Prime interest to identify smallmolecule catalytic DNA-PK inhibitors
was motivated by the role of this enzyme in cellular DNA repair andsuch therapeutic approaches were thus assumed to act as potent
radio- or chemosensitizers. Over the past two decades, numerous
DNA-PK inhibitors greatly differing in their potency, selectivity and in-
hibition reversibility have been described. This includes the very early
non-specific compounds such as caffeine (Sarkaria et al., 1999) or
wortmannin (Izzard et al., 1999; Sarkaria et al., 1998) as well as highly
potent selective inhibitors that are evaluated in current clinical trials
(Fig. 4).
4.1.1. Early DNA-PK inhibitors
Sarkaria et al. reported already in 1999 that the radiosensitizing
agent caffeine inhibits in vitro kinase activities of the twoDDRmaster ki-
nases ATM and ATR (Sarkaria et al., 1999). Later on it has been found
that caffeine also inhibits immunoprecipitated and purified DNA-PK as
well as DNA-PK in cell extracts (Block et al., 2004). The fungus-
derived steroid metabolite wortmannin, which non-specifically inhibits
PI3K family kinases,was also identified as a relatively potent inhibitor of
DNA-PK and ATM activities (Sarkaria et al., 1998). Wortmannin forms
covalent adducts with Lys3751 of DNA-PKcs's kinase domain and in-
hibits its activity via a non-competitive mechanism (Izzard et al.,
1999). In 2003, Durant and Karran showed that a naturally occurring
food component vanillin and its derivatives block DNA end joining by
direct inhibition of DNA-PK activity and significantly potentiate
cisplatin-mediated cytotoxicity (Durant and Karran, 2003). Although
often used as tool compounds, the poor selectivity, water solubility or
relative structural complexity of these early anti-DNA-PK molecules
restricted their use to preclinical studies.
4.1.2. LY294002 as a lead compound
Due to high homology of their kinase domains, the search for DNA-
PK inhibitory strategies was to a high extent paralleling development
of specific PI3K inhibitors. At the onset of these attempts was quercetin,
a naturally-occuring flavonoid that acts as an ATP-competitive antago-
nist for the kinase domain of PI3K and other kinases. In 1994, following
a screen of quercetin-derived molecules, the chrome-4-one compound
LY294002 (2-(4-morpholinyl)-8-phenylchromone) has been reported
as a specific inhibitor of PI3K that equally potently inhibits also DNA-
PK (IC50 = 1.5 μM) andmTOR (Vlahos et al., 1994) (Griffin et al., 2005).
Later on, LY294002 became a lead compound to develop more spe-
cific and more potent ATP-competitive DNA-PKcs inhibitors such as
NU7441 (IC50 vs. DNA-PK = 13 nM), NU7427 (40 nM), NU7026 (0.23
μM) or NU7163 (0.19 μM) (Griffin et al., 2005; Hardcastle et al., 2005;
Hollick et al., 2003; Leahy et al., 2004) (Fig. 4B). Preclinical evaluations
of these novel potent kinase inhibitors revealed their radio- and
chemosensitization potential when combined with external DNA dam-
age. NU7427 sensitized HeLa cells to IR in vitro and potentiated cytotox-
icity of the topoisomerase II inhibitor etoposide (Hardcastle et al., 2005)
whereas NU7026 was shown to increase cytotoxicity of various topo-
isomerase II poisons in leukemia cells (Willmore et al., 2004). The
more potent NU7441 increased the cytotoxicity of IR and etoposide in
DNA-PKcs-proficient but not in DNA-PKcs-deficient human colon can-
cer cells regardless of their p53 status, substantially retarded the repair
of IR- and etoposide-induced DSBs and appreciably increased G2/M cell
cycle phase accumulation induced by IR, etoposide, and doxorubicin
(Zhao et al., 2006). In vivo, NU7441 increased etoposide-induced
tumor growth delay without exacerbating etoposide toxicity (Zhao
et al., 2006). Subsequently, numerous independent studies utilizing
NU7441 as a DNA-PK inhibitor in preclinical models reported similar
observations in context of various tumor types such as breast cancer,
NSCLC, liver cancer or leukemia (Alikarami et al., 2017; Ciszewski
et al., 2014; Cowell et al., 2005; Tichy et al., 2014; Yanai et al., 2017;
Yang et al., 2016).
Unfortunately, clinical testing and implementation of these com-
pounds could not be pursued due to their suboptimal pharmacological
profiles. For example, based on pharmacokinetic simulations, Nutley
et al. predicted that NU7026 would have to be administered four
Table 2
Specific DNA-PK inhibitors in clinical trials (data fromwww.clinicaltrials.gov (last accessed on 30th March 2020)).
Trial Drug Target Combinations Cancer type Phase
NCT01353625 CC-115 DNA-PK/mTOR Monotherapy GBM, HNSCC, prostate, Ewing's osteosarcoma, CLL, neoplasm metastasis Phase I
NCT02833883 CC-115 DNA-PK/mTOR Enzalutamide Prostate Phase I
NCT02977780 CC-115 DNA-PK/mTOR Radiotherapy GBM Phase II
NCT02316197 M3814 DNA-PK Monotherapy Advanced solid tumors, CLL Phase I
NCT02516813 M3814 DNA-PK Radiotherapy, cisplatin Advanced solid tumors Phase I
NCT03724890 M3814 DNA-PK Avelumab, radiotherapy Advanced solid tumors Phase I
NCT03770689 M3814 DNA-PK Capecitabine, radiotherapy Rectal Phase I/II
NCT03983824 M3814 DNA-PK Mitoxantrone, etoposide, cytarabine AML Phase I
NCT04172532 M3814 DNA-PK Radiotherapy Pancreatic Phase I/II
NCT04092270 M3814 DNA-PK PLD Ovarian Phase I
NCT04071236 M3814 DNA-PK Radium-223 dichloride, avelumab Prostate Phase I/II
NCT04068194 M3814 DNA-PK Avelumab, radiotherapy Advanced solid tumors, hepatobiliary malignancies Phase I/II
NCT04266912 M3814 DNA-PK Avelumab Advanced solid tumors with DDR genes aberrations Phase I/II
NCT03907969 AZD7648 DNA-PK Monotherapy, PLD, olaparib Advanced malignancies PhaseI/IIa
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quired for radiosensitisation (Nutley et al., 2005). An attempt to opti-
mize pharmacokinetics of these compounds led to synthesis of very
potent NU7441 analogs (IC50 vs. DNA-PK = 8 nM) (Cano et al., 2010),
suggesting that such modifications could lead to the desired outcome.
Homology model of the ATP-binding site of DNA-PK based on PI-3
Kγ guided subsequent design of small molecule inhibitors with im-
proved characteristics such as KU-0060648 (Cano et al., 2013;
Clapham et al., 2012). Although KU-0060648 displayed very promising
biological activity (IC50 vs. DNA-PK of 0.02 μM in MCF7 and 0.17 μM in
SW620 cells) including chemo- and radiosensitization potential and im-
proved drug-like properties compared to NU7441, counter screen
against other PIKK family members revealed that this compound as
well as the other synthesized analogues were in fact very potent dual
DNA-PK and PI3K inhibitors (Cano et al., 2013;Munck et al., 2012). Sim-
ilarly, theDNA-PKATP-competitive inhibitor SU11752was shown to in-
hibit also PI-3 K p110γ (Ismail et al., 2004) whereas the specific ATM
inhibitor KU55933 was reported to bear considerable DNA-PK inhibi-
tory activity (Hickson et al., 2004). Similarly, Hisatomi et al. have sug-
gested in 2011 the topoisomerase IIα inhibitor NK314 as a dual
topoisomerase and DNA-PK inhibitory molecule by showing that
NK314 potentiates its antitumor activity in adult T-cell leukemia/lym-
phoma cells by inhibition of dual targets (Hisatomi et al., 2011).
Very recently, Willoughby et al. reported that NU5455, a newly
identified highly selective oral DNA-PKcs inhibitor, preferentially aug-
mented the effect of targeted radiotherapy on human orthotopic lung
tumors without influencing acute DNA damage or a late radiation-
induced fibrosis (Willoughby et al., 2020). Furthermore, while
NU5455 administration increased both the efficacy and the toxicity
of parenterally administered topoisomerase inhibitor, it enhanced
the activity of doxorubicin released locally in liver tumor xenografts
without inducing any adverse effects (Willoughby et al., 2020).
These findings are of particular importance for the treatment of HCC
as in clinical scenarios, local treatments (localized doxorubicin-
eluting beads) are being used (Lammer et al., 2010) and DNA-PKcs ac-
tivity has been reported to confer resistance to these treatments
(Cornell et al., 2015). Transient pharmacological inhibition of its activ-
ity by NU5455 is effective and tolerable when combined with local-
ized DNA-damaging therapies and thus has promising clinical
potential (Willoughby et al., 2020).
4.1.3. IC60211 derivatives
Another class of selective anti-DNA-PK compounds used in preclini-
cal studies comprises molecules from the series of morpholine-
containing inhibitors derived by optimization from the arylmorpholine
IC60211 (IC50 = 400 nM) from the ICOS Corporation small molecule li-
brary (Kashishian et al., 2003; Knight et al., 2004; Shinohara et al., 2005)
(Fig. 4C). IC86621, IC486154, IC87102 and the most selective IC87361all maintain the arylmorpholine substructure and are highly potent
(IC50 = 120 nM, 44, 35 and 34, respectively) (Kashishian et al., 2003;
Knight et al., 2004; Shinohara et al., 2005). Although IC86621 with an
IC50 of 120 nM is not themost active of these compounds, it can be easily
synthesized (Chandra et al., 2012), is chemically stable and thus became
the most used representative of these inhibitors (Allen et al., 2003;
Bailey et al., 2004; Peddi et al., 2010; Yang et al., 2009a, 2009b; Yasaei
et al., 2013; Yasaei and Slijepcevic, 2010). IC86621 was shown to en-
hance cellular toxicity of etoposide and bleomycin but not the one of
doxorubicine, cisplatin, 5-FU, paclitaxel or vinblastine, indicating that
its activity specifically affects cellular metabolism of DNA DSBs but not
of single-stranded DNA breaks or other DNA lesions (Kashishian et al.,
2003). Structurally different small molecule DNA-PK inhibitor
IC486241, which possesses an acridinone core, was found to synergize
with irinotecan to enhance colon cancer cell death (Davidson et al.,
2012a, 2012b) and to sensitize breast cancer cell lines to doxorubicin
and cisplatin (Davidson et al., 2012a, 2012b).
Importantly, although IC86621 and related compounds all display
certain activity against the closely related PI3Ks, they appear benign in
the absence of exogenous DSBs at concentrations of up to 50 μM
(Kashishian et al., 2003). Nevertheless, with the aim of avoiding the
risk of radiosensitization of normal tissue, Wong et al. has recently re-
ported development of SN38023, a novel bioreductive pro-drug that is
metabolized to IC87361 selectively in radioresistant hypoxic cells
(Wong et al., 2019).
4.2. DNA-PK inhibitors in clinical trials
As outlined in the previous chapter, clinical testing of DNA-PK inhi-
bition has been initially tampered by the lack of specificity and insuffi-
cient pharmacokinetic properties of the early inhibitors. The two
Celgenedrugs, CC-115 andCC-122,were among thefirst to be evaluated
in clinical settings, followed by a pan-PI3K inhibitor ZSTK474 (Zenyaku
Kogyo Co., Ltd.) that targets also DNA-PK, and the selective DNA-PK in-
hibitors VX984 (M9831; Vertex Pharmaceuticals and Merck KGaA),
M3814 (EMD Serono Research & Development Institute, Inc.) and
AZD7648 (AstraZeneca), currently tested in numerous trials (Table 2;
Fig. 4C).
4.2.1. CC-115, a dual DNA-PK and mTOR inhibitor
CC-115 has been synthesized and reported by Mortensen et al. in
2015 as a triazol-containing mTOR inhibitor with pharmacokinetic
properties that granted its further clinical development (Mortensen
et al., 2015). Later on, Tsuji et al. have reported the characterization of
the DNA-PK inhibitory activity of CC-115 in vitro, proving that this com-
pound inhibits DNA-PKcs autophosphorylation at Ser2056 and prevents
NHEJ by inhibiting the dissociation of DNA-PKcs, XRCC4, and DNA ligase
IV from DNA ends (Tsuji et al., 2017). Interestingly, using CC-115 they
Fig. 4. Chemical structures of representative DNA-PK inhibitors: (A) early compounds, (B) LY294002 and related inhibitors, (C) IC series, (D) compounds in clinical trials (drawings of
chemical structures were produced by ChemSpider).
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loss of functional ATM, a finding thatwould also support CC-115 clinical
development in patients with ATM-deficient tumors.CC-115 as a dual DNA-PK/mTOR inhibitor is a promising compound
formanagement of CLL as in this disease, B-cell receptor (BCR) signaling
inhibition provides clinical benefit to patients but acquired resistance
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preclinical studies have reported encouraging data (Thijssen et al.,
2016).
NCT01353625 was the first-in-human Phase I study of CC-115, initi-
ated back in 2011, with a total of 118 enrolled participants. The main
purpose of this study was to assess the safety and action of this new
class of experimental dual kinase inhibitors targeting DNA-PK and
mTOR in patients with advanced tumors (solid and hematologic malig-
nancies) unresponsive to standard therapies and to determine the ap-
propriate dose and tumor types for later-stage clinical trials. Already
in 2016, Thijssen et al. have reported promising results concerning
early clinical activity of CC-15 in patients with CLL (Thijssen et al.,
2016). BCR-mediated signaling was inhibited by CC-115 in CLL samples
obtained from patients with acquired resistance to the approved PI3K
inhibitor idelalisib (Thijssen et al., 2016). Clinically, 7 out of 8 evaluated
study participants with relapsed/refractory CLL/small lymphocytic lym-
phoma that harbored mutations or deletions in the ATM gene had a de-
crease in lymphadenopathy, resulting in 1 partial response (PR) and 3
PRs with lymphocytosis (Thijssen et al., 2016).
More recently, a study on dose-finding and cohort-expansion phases
(74 patients) of the NCT01353625 trial has revealed that CC-115 was
well tolerated and the observed toxicities were consistent with those
reported for mTOR inhibitors (Munster et al., 2019). These included in
the dose-finding cohort (44 patients) thrombocytopenia, stomatitis, hy-
perglycemia, asthenia/fatigue and increased transaminases whereas in
the cohort expansion (74 patients, 5 specified tumor types), for which
CC-115 10mg BIDwas selected, fatigue, nausea, and decreased appetite
were the most frequently observed (Munster et al., 2019).
Concerning preliminary efficacy of CC-115, a patient with endome-
trial carcinoma remained in complete remission for more than 4 years
and 38% and 25% of CLL/small lymphocytic lymphoma patients had PR
and stable disease (SD), respectively (Munster et al., 2019). SD was
also reached in 53%, 22%, 21%, and 64% of patients with HNSCC, Ewing
sarcoma, GBM, and castration-resistant prostate cancer, respectively
(Munster et al., 2019). Out of twelve additional patients with mixed
solid tumors that participated in a bioavailability substudy, 2 experi-
enced PR and 4 SD (Munster et al., 2019).
Currently, two other studies, NCT02833883 and NCT02977780, are
assessing the dual DNA-PK and mTOR inhibition potential of CC-115 in
clinical settings. NCT02833883 is a Phase 1b study combining CC-115
with the nonsteroidal antiandrogen enzalutamide for treatment of
men with castration-resistant prostate cancer. Results of this trial,
whichhas been initialized in July 2016 atMemorial SloanKetteringCan-
cer Center andhas recruited 40participants, are expected to be available
by July 2021. The prime purpose of the INdividualized Screening Trial of
Innovative Glioblastoma Therapy (INSIGhT) study (NCT02977780) led
byPatrickY.Wen (Dana Faber Cancer Institute) is to evaluate various in-
vestigational drugs such as abemaciclib (a Cdk4/6 inhibitor), neratinib
(a dual HER2/EGFR tyrosine kinase inhibitor) and CC-115 as a possible
treatment for GBM patients. INSIGhT estimates recruitment of 280 par-
ticipants and will be concluded by mid-2022.
Concerning potential resistance mechanisms towards CC-115 treat-
ment, Beebe and Zhang have reported in their recent preclinical study
that CC-115 is a substrate of ATP-binding cassette G2 (ABCG2) and sug-
gested that expression of ABC transporters, including ABCB1 and
ABCG2, may affect the outcome in clinical trials testing CC-115 (Beebe
and Zhang, 2019). Moreover, their data indicate that ABC transporters
may be used as markers for future precision use of CC-115.
4.2.2. CC-122 and ZSTK474 as non-selective DNA-PK targeting
Avadomide (CC-122), a pleiotropic pathway modifier compound
originally developed for broad diffuse large B-cell lymphoma (DLBCL)
and with activity against DNA-PK (Goodwin and Knudsen, 2014;
Trenner and Sartori, 2019), is studied in Phase I first-in-human study
in patients with advanced solid tumors, non-Hodgkin's lymphoma
(NHL), or multiple myeloma (NCT01421524; 271 participants). Inthree DLBCL patients included in this trial, CC-122 was shown to regu-
late the natural killer cells phenotype and its activity due to the reduced
accumulation of myeloid-derived suppressor cells and eventually de-
crease the T regulatory lymphocytes subsets and the activation of T
cells through co-stimulatory molecule CD28 was detected as a delayed
CC-122 effect (Cubillos-Zapata et al., 2016). Later on, Rasco et al. re-
ported that avadomide monotherapy demonstrated acceptable safety
and favorable pharmacokinetics in these patients, with 3 objective re-
sponses observed for NHL cases (Rasco et al., 2019). Furthermore,
among 84patientswith de novo relapsed or refractory DLBCL, overall re-
sponse rate to this drug with immunomodulatory and direct antitumor
activities was 29%, including 11% of complete responses (Carpio et al.,
2020). Avadomide is currently being evaluated for various indications
in combinationwith other therapeutics such as the checkpoint inhibitor
nivolumab in unresectable HCC and advanced melanoma. However, as
CC-122 is a small-molecule therapeutic agent that primarily modulates
the cereblon E3 ligase activity, its effects as an anti-DNA-PK compound
are rather difficult to estimate.
Similarly, ZSTK474 (Zenyaku Kogyo Co., Ltd.), a pan-PI3K inhibitor
that to some extent inhibits also DNA-PK (Kong and Yamori, 2010),
has been tested in two phase I clinical trials (NCT01280487 and
NCT01682473) for advanced solid malignancies. Plausible contribution
of its DNA-PK-targeting properties to the overall treatment efficacy is
however unknown.
4.2.3. VX984 (M9831), M3814 and AZD7648: specific DNA-PK catalytic
inhibitors
VX984 (M9831; Vertex Pharmaceuticals, Merck KGaA) is a catalytic
DNA-PK kinase inhibitor, which was shown to efficiently inhibit NHEJ,
resulting in compensatory increases in alternative repair pathways,
preferentially in transformed cells (Khan et al., 2018). When evaluated
in combination with irradiation in preclinical GBM models, enhanced
radiosensitivity was observed in vitro as well as in orthotopic xeno-
grafts, indicating that this compound crosses the blood-brain barrier
at sufficient concentrations (Timme et al., 2018). VX984 has been tested
clinically solely in the first-in-human phase I trial (NCT02644278),
which has been initiated in the US in December 2015. The purpose of
this study was to evaluate the safety and tolerability of VX984 adminis-
tered alone and in combination with PLD, and to determine the maxi-
mum tolerated dose (MTD) and preliminary evidence of efficacy of
VX984 in combination with PLD in participants with advanced solid tu-
mors. However, the study with 15 enrolled participants has been pre-
maturely discontinued during the dose escalation part based on
business-related reasons.
M3814 (MSC2490484A, nedisertib, peposertib; Merck KGaA) is an
investigational drug that is being evaluated for the treatment of subjects
with advanced solid tumors or CLL that likely differs from other cancers
in the mode of DNA repair. In vitro, M3814 sensitized multiple tumor
cell lines to radiation therapy and strongly enhanced the antitumor ac-
tivity of ionizing radiation in vivowith complete tumor regression upon
fractionated radiation (Zenke et al., 2020). These effects are due to inhi-
bition of DNA-PK protein kinase activity as demonstrated by the levels
of DNA-PK autophosphorylation in human tumor cell lines, and xeno-
graft tumors (Zenke et al., 2020).
Recent preclinical studies have reported activity of M3814 in combi-
nations with other therapeutic approaches in various tumor types. In
this respect, Klein et al. have shown in 2017 that DNA-PK inhibition
by M3814 combined with either photon or carbon ion irradiation over-
comes hypoxia-induced radioresistance in NSCLC models (Klein et al.,
2017). More recently, Wise et al. have evaluated the activity of M3814
in combinationwithmultiple topoisomerase II inhibitors in ovarian can-
cer xenografts (Wise et al., 2019). In these models, M3814 had only a
limited efficacy as a monotherapy but in combination with PLD, en-
hanced activity has been observed as compared to PLD treatment
alone. Importantly, M3814 has been well tolerated. In the context of
acute myeloid leukemia, the 2020 data by Carr et al. propose M3814
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from a new generation of antibody drug conjugate therapies aiming
with increased specificity at the acute leukemia cell compartment
(Carr et al., 2020).
Mechanistically, Sun et al. have reported that M3814 effectively
blocks the repair of radiation-induced DSBs and potently enhances
p53 phosphorylation and activation (Sun et al., 2019). Interestingly,
whereas upon the combined M3814/irradiation treatment the p53
wild-type cells underwent a complete p53-dependent cell cycle arrest
and premature cell senescence, p53-deficient cell lines experiencedmi-
totic catastrophe and apoptotic cell death due to cell cycle progression
despite a DNA damage load (Sun et al., 2019). These data identify p53
as a possible biomarker for response of cancer cells to combination
treatment with radiation and a DNA-PK inhibitor and suggest that p53
mutation status should be considered in the design of future clinical
testing.
M3814has been initially tested in twophase I clinical trials asmono-
therapy (NCT02316197; 31 participants) or in combination with
(chemo-)radiotherapy (NCT02516813; 155 participants). In both trials
patients were treated with ascending doses of M3814 to establish the
safety and maximum tolerated dose (MTD) or recommended phase 2
dose (RP2D) (primary endpoint) and efficacy (secondary endpoint).
Based on preliminary results, M3814 has been well tolerated as mono-
therapy (most frequent adverse events in NCT02316197 were nausea,
vomiting, decreased appetite, constipation, diarrhea, pyrexia, fatigue,
and rash, whereas in NCT02516813 (first 16 patients), dysphagia,
prolonged mucosal inflammation/ stomatitis and radiation skin injury)
and the RP2D of 400 mg BID has been selected (Mau-Sorensen et al.,
2018). Pharmacodynamics in surrogate tissue showed robust inhibition
of the induction of phospho-DNA-PK inhibition for up to 6h and
whereas no objective responses were reported in the monotherapy
trial, while in the combined settings (M3814 administered 1,5 h prior
IR/IR + cisplatin), durable in field responses were seen in 7 out of 16
evaluated patients (Mau-Sorensen et al., 2018).
Following these two trials, numerous other studies evaluating
M3814 in combination with other therapies are currently ongoing.
Among them is the phase I study testing avelumab-M3814 combi-
nations with and without radiotherapy in participants with se-
lected advanced or metastatic solid tumors (NCT03724890;
recruiting, estimated 34 participants), the phase I/II study of
M3814 in combination with capecitabine and radiotherapy in
locally-advanced rectal cancer (NCT03770689; recruiting, esti-
mated enrollment 160 patients), NCI-sponsored trials
NCT03983824 (M3814 in combination with Mitoxantrone,
Etoposide, and Cytarabine for Relapsed or Refractory Acute Mye-
loid Leukemia), NCT04172532 (a phase 1/2 Study of M3814 in
combination with hypofractionated radiotherapy for the treat-
ment of unresectable locally advanced pancreatic adenocarci-
noma), NCT04092270 (a phase I/Ib dose escalation study of
pegylated liposomal doxorubicin with M3814 in ovarian cancer),
NCT04071236 (a phase I/II study of Radium-223 Dichloride,
M3814 and avelumab for Advanced Prostate Cancer Not Respon-
sive to Hormonal Therapy), NCT04068194 (a phase I/II study of
M3814 and avelumab in combination with hypofractionated radi-
ation in patients with advanced/metastatic solid tumors and
hepatobiliary malignancies) as well as the NCT04266912 phase
I/II study aiming at the evaluation of avelumab and M6620 or
M3814 (nedisertib) for the treatment of DDR-deficient metastatic
or unresectable solid tumors.
Early this year, Goldberg et al. reported AZD7648 as a very potent
and highly selective DNA-PK inhibitory molecule that resulted from a
screen of AstraZeneca's corporate collection for DNA-PKcs inhibitors
with good PI3K selectivity (Goldberg et al., 2020). Optimization of the
best hit focused on further increase in selectivitywhile improving phys-
ical and pharmacokinetic properties such as co-optimization of perme-
ability and metabolic stability. AZD7648 did not display any significantoff-target activity in the protein kinome and only weak activity versus
PI3Kα/γ lipid kinases. Monotherapy activity in murine xenograft
models was observed.
Concerning combinations with relevant anticancer therapies,
AZD7648 sensitized xenografts and patient-derived xenografts to
radiation- and doxorubicin-induced DNA damage and induced
sustained regressions in these models (Fok et al., 2019). In addition,
AZD7648 was efficient also in combinations with the PARP inhibitor
olaparib by increasing genomic instability, resulting in cell growth inhi-
bition, apoptosis and sustained tumor regressions.
Based on the promising preclinical findings, AZD7648 has
progressed into clinical testing. NCT03907969 is a modular Phase I/IIa
clinical trial to evaluate AZD7648 alone and in combination with other
anticancer agents such as doxorubicin or olaparib in patients with ad-
vanced solid cancers. The study, which is currently recruiting partici-
pants (estimated enrollment of 234 patients), is expected to be
concluded early in 2024.5. Concluding remarks and perspectives
The fundamental role that DDR effectors play in cell physiology by
preserving genome stability, thereby averting malignant transforma-
tion, has become an established dogma during recent decades. Conse-
quently, and with the introduction of PARP inhibitors as a routine
pharmacological approach in the case of BRCA1/BRCA2 deficient tu-
mors, the repertoire of additional DDR targets that are aberrantly
expressed in cancer, is expected to steadily expand in the near future
to come (Yap et al., 2019). A host of preclinical and clinical findings
has been accumulating that suggests that both a decrease and an in-
crease in DNA-PK status and activity is a characteristic present in nu-
merous tumors and tumor models. In the emerging era of precision
medicine, we foresee that it will be of utmost importance to apply pa-
tient stratification parameters in order to identify and select thepatients
who could benefit from DNA-PK inhibitors that are already available
and the next generations compounds, which will appear in the upcom-
ing future. To that end, much work is probably still required where the
biology of particular genomic alterations is still not optimally clarified as
for example in the case of the various Ku70, Ku80 and DNA-PKcs SNPs.
In other words, it will be essential to determine in this instance the rel-
evance of a particular DNA-PK variant found in a tumor for the treat-
ment with a particular DNA-PK inhibitor. To that end, there is
currently still a gap with preclinical studies that should clarify the biol-
ogy of those polymorphism variants to explain their particular associa-
tion with patient prognosis.
An important aspect of the use of DNA-PK inhibitors in the clinic is
the determination of a full broad of combinations with other treatment
modalities, which could deliver optimal treatment results. In that con-
text, combining those inhibitors with any DDAs in addition to RT
could be of a therapeutic benefit in terms of tumor sensitization. Obvi-
ously, expanding such combined treatment also to other modalities as
specific kinase inhibitors and immunotherapies could translate into ef-
ficient next generation protocols.
Importantly, DNA-PK targeting could also be investigated in the con-
text of HRdeficiency aswith BRCA1/BRCA2 deficient breast, ovarian and
pancreatic cancers in combination with PARP inhibitors. The corre-
sponding additional blocking of NHEJ in these tumors with another
DDAs intervention could have an added therapeutic impact that needs
to be determined.
Obviously, targeting DNA-PK is predominantly likely to have sensi-
tizing effects to DDAs in tumors with increased NHEJ activity. In tumors
exhibiting decreased DNA-PK activity, a strategy that would target HR
factors is worthwhile to be explored. An additional path that has not
been yet explored effectively are screenings, using CRISPR or pharmaco-
logic libraries, for identification of targetable proteins that could form
synthetic lethal interactions with DNA-PK (Kantidze et al., 2018).
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DDR is another tremendously important feature that without doubt
could be extended to additional tumor types beyond prostate cancer.
The fact that an originally-defined DDR effector regulates networks
that control tumor metastasis and that its inhibition can interfere with
this attribute of tumor progression are remarkable findings with game
changing potential. It would be certainly of utmost importance to reveal
whether interphases similar to the one between the AR and DNA-PK in
prostate cancer exist and are relevant to other hormone receptors that
control tumorigenesis of other tissues. Obviously, the significance of
such questions would foremost apply to the ER and PR in breast cancer.
Notably, during the last two decades, interesting findings that point
to a signaling crosstalk between the DDR and growth factor receptor ty-
rosine kinases, which are major cancer drivers have been reported. The
interplay between pathways driven by the EGFR and DNA-PK is of rele-
vance as discussed above. Naturally, it would be of high interest to fur-
ther determine whether other RTKs may have similar interactions with
the DNA-PK complex and how inhibition or co-inhibition of those re-
ceptors with DNA-PK targeting may affect various tumor features as
growth and responses to DDAs.
Finally, as resistancemechanisms ultimately evolve with almost any
targeting approach, it is probably fair to speculate that this will happen
also when DNA-PK inhibitors will find the way to the clinic. Identifying
potential resistances to the DNA-PK inhibitors in preclinical setting
might, as it has been shown in other cases, to be beneficial for patients.
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